KCA
Search
- Page Path
- HOME > Search
Original Articles
- Trends in Incidence and Survival of Childhood and Adolescent Cancer in Korea, 2001–2020: Comparison with U.S. SEER Data
- Jin Kyung Suh, Eun Hye Park, Meerim Park, Jun Ah Lee, Kyu-won Jung, Hyeon Jin Park
- Received July 10, 2025 Accepted December 30, 2025 Published online January 2, 2026
- DOI: https://doi.org/10.4143/crt.2025.722 [Epub ahead of print]
-
Abstract
PDF
PubReader
ePub - Purpose
Childhood cancers are rare but clinically significant. Monitoring incidence and survival trends is essential for evaluating progress in cancer control and identifying areas for improvement.
Materials and Methods
We analyzed cancer incidence and survival trends among individuals aged 0-19 years in Korea using data from the Korea Central Cancer Registry from 2001 to 2020. Cancer types were classified according to the International Classification of Childhood Cancer, third edition (ICCC-3). Age-standardized incidence rates (ASRs) and annual percent changes (APCs) were calculated. Relative survival rates (RSRs) were estimated and compared with data from the United States.
Results
A total of 34,223 cancer cases were identified during the study period. The overall ASR was 151.3 per million person-years, with a significant increasing trend (APC 1.5%). Leukemias were the most common diagnostic group (ASR 43.7), followed by central nervous system tumors and lymphomas. Between 2001-2010 and 2011-2020, the 5-year and 10-year RSRs improved from 75.2% to 84.8% and from 72.7% to 82.7%, respectively. The largest survival gains were observed in leukemia (14.9 percentage points) and neuroblastoma (13.1 percentage points). Compared to Surveillance, Epidemiology, and End Results (SEER) data, Korea showed similar overall survival trends, although differences remained by cancer type and age group.
Conclusion
The incidence of childhood and adolescent cancers in Korea has increased, while survival has significantly improved over the past two decades. These findings highlight substantial progress in pediatric cancer care, while underscoring the need for targeted efforts for specific cancer subtypes and age groups.
- 1,143 View
- 64 Download
- Lung and Thoracic cancer
- Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015
- Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu-Won Jung, Chi Young Jung, Jeong Su Cho, Yoo-Duk Choi, Seung-Sik Hwang, Chang-Min Choi, Korean Association for Lung Cancer, Korea Central Cancer Registry
- Cancer Res Treat. 2023;55(1):103-111. Published online June 20, 2022
- DOI: https://doi.org/10.4143/crt.2022.264
-
Abstract
PDF
Supplementary MaterialPubReaderePub - Purpose
This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.
Materials and Methods
The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.
Results
We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non–small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (EGFR) mutation (19% vs. 11%) or anaplastic lymphoma kinase (ALK) translocation (38% vs. 11%).
Conclusion
In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease. -
Citations
Citations to this article as recorded by
- Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial
Niels Reinmuth, Sébastien Couraud, Luis Paz-Ares, Marina Chiara Garassino, Shobhit Baijal, Davey Daniel, Pilar Garrido, Terufumi Kato, Ivor Percent, Achim Rittmeyer, Hector Soto Parra, Sabeen Mekan, Mira Patel, Matthew Radford, Eric Zhang, Christopher G.
JTO Clinical and Research Reports.2026; 7(2): 100929. CrossRef - Exploring Sex and Clinical Factors Associated with Long-Term Survival After Implantable Cardioverter-Defibrillator Implantation: A 10-Year Cohort Study
Rebeca Lorca, María Salgado, Cristina Helguera, Alberto Alen, Francisco González-Urbistondo, Rosana González-Mesa, Paula Bouzón, Daniel García, Rodrigo Di Massa, Rut Álvarez-Velasco, José Manuel Rubín, Pablo Avanzas
Journal of Clinical Medicine.2026; 15(3): 1275. CrossRef - Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC
Subhamoy Chakraborty, Andrew Elliott, Utsav Sen, Charles Coleman, Vrinda Jethalia, Kedwin Ventura, Chih-Wei Fan, Ramja Sritharan, Avisek Banerjee, Yazhini Mahendravarman, Ari Vanderwalde, Balazs Halmos, Elisa de Stanchina, Hirokazu Taniguchi, Deniz Demirc
Nature Communications.2026;[Epub] CrossRef - Formulation of pullulan-assisted nanoparticles for improved dasatinib cytotoxicity in A549 lung carcinoma cells
Sunita S. Shinde, Aishwarya A. Lohar, Avinash H. Hosmani, Sameer J. Nadaf, Rohit R. Shah
Zeitschrift für Naturforschung C.2026;[Epub] CrossRef - Fragment-Based De Novo Discovery of Fourth-Generation EGFR-L858R/T790M/C797S-Tyrosine Kinase Inhibitors Targeting Catalytic Lys745 Residue to Overcome the Osimertinib Resistance
Prasanna Joshi, Manisha Modak, Harun Patel
Journal of Computational Biophysics and Chemistry.2026; 25(11): 2793. CrossRef - Design and application of a novel acridine-based fluorophore BAA12C as a theranostic agent
Dat Thanh Dinh, Chia-Ying Li, Ryan Joshua Liou, Xuan-Yu Chen, Min-Wei Wu, Cheng-Chung Chang
Sensors and Actuators Reports.2026; 11: 100460. CrossRef - Integrated analysis of therapeutic strategies and prognostic factors in advanced lung adenocarcinoma: Retrospective study with emphasis on gene assays, multimodality treatment approaches and predictive machine learning models
Shingchern You, Shiuan-Wen Chen, Irene Chen, Wei-Teing Chen
Oncology Letters.2026; 31(5): 1. CrossRef - FTO Acts as a Suppressor Gene to Inhibit the Translation of KDM5A mRNA by Demethylating m6A Modifications in Lung Adenocarcinoma
Wen Zhao, Chen Zhu, Ning Wang, Bin Wu, Xuelin Lu, Ye Xu, Zhijie Xu
International Journal of Genomics.2026;[Epub] CrossRef - Identification of Prognostic Risk Factors in Older Patients With Extensive‐Stage Small Cell Lung Cancer
Jiayin Liu, Xun Liu, Xiaolin Li, Ning Liu, Bo Wang, Li Feng, Zhisong Fan, Long Wang, Jing Han, Xue Zhang, Hui Jin, Dan Li, Yan Liu, Jing Zuo, Yudong Wang
Cancer Medicine.2026;[Epub] CrossRef - Trends and Outcomes of Lung Cancer Surgery in South Korea
Joon Beom Park, Su-Jin Cho, Myung-Il Hahm, Danbee Kang, Seong Yong Park
Cancer Research and Treatment.2026; 58(2): 443. CrossRef - Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review
Evangeline Samuel, S. Tissera, E. Paul, J. Zalcberg, R. G. Stirling
Aging and Cancer.2026;[Epub] CrossRef - Real‐World Treatment and Outcomes in Resectable Early‐Stage Non‐Small Cell Cancer: THASSOS‐INTL Australia Cohort
Pei Ding, Kevin Jasas, Victoria Bray, Abhijit Pal, Rebecca Moor
AGING MEDICINE.2026; 9(2): 137. CrossRef - Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors
Lai Wei, Mengxing Tian, Qian Han, Wen Wang, Xin Jin, Xintian Xu
Clinical Nutrition ESPEN.2026; 73: 103288. CrossRef - AptoDetect™-Lung Assay as a Blood-Based Predictor of Advanced-Stage Lung Cancer in Patients with Lung-RADS 3–4 Pulmonary Nodules: A Multicenter Prospective Cohort Study
Bora Lee, Chi Young Kim, Jung Seop Eom, Wonjun Ji, Min Jee Kim, Sung Hoon Yoon, June Hong Ahn, Jun Hyeok Lim, Chaeuk Chung, Dong Won Park, Seung Hyeun Lee, Chang Dong Yeo
Biomedicines.2026; 14(5): 1013. CrossRef - Functional Precision Oncology Approach Using Nanoliter Droplet Array for Drug Sensitivity Testing in Lung Cancer
Maryam Salarian, Vicky L. Schiling, Thomas Muley, Michael Allgäuer, Florian Eichhorn, Michael Meister, Marc A. Schneider, Anna A. Popova
Advanced Healthcare Materials.2026;[Epub] CrossRef - Differences in long-term survival according to the underlying cardiomyopathy indication for implantable cardioverter-defibrillator implantation
Rebeca Lorca, Paula Bouzón, Fernando López, María Salgado, Rosana González-Mesa, Francisco González-Urbistondo, Cristina Helguera, Alberto Alen, Alvaro Lorente, Rut Alvarez-Velasco, José Manuel Rubín, Pablo Avanzas
International Journal of Cardiology.2026; 458: 134561. CrossRef -
SLC2A1-Dependent Ketone Metabolism Regulates Tumor Progression and Immunotherapy Efficacy in Lung Adenocarcinoma
Xing Feng, Li Gao, Yonggang Xue, Yanbing Zhang, Hongyou Cao, Tianchang Wange
Critical Reviews in Immunology.2026; 46(2): 59. CrossRef - AI-Driven Preoperative Chest Radiograph Analysis for Prognostic Stratification in Surgically Resected Pathological Stage 1 Non-Small Cell Lung Cancer
Hyun Joo Shin, Eun Hye Lee, Se Hyun Kwak, Na Young Kim, Eun-Kyung Kim, Young Joo Suh
Journal of Imaging Informatics in Medicine.2026;[Epub] CrossRef - Novel strategy of pemetrexed combined with localized therapy: breakthrough impact of long-term maintenance regimen on patient survival—a case report
Dan Liu, Xiaobiao Ma, Chunlei Ge, Qian Huang, Yiqing Duan, Li Li
Journal of Medical Case Reports.2026;[Epub] CrossRef - Molecular‐Based Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage Lung Cancer: A Systematic Review and Meta‐Analysis
Aaron Ling, Evangeline Samuel, Rahini Mahendran, John Zalcberg, Rob G. Stirling
Thoracic Cancer.2026;[Epub] CrossRef - Weight loss as a predictor of reduced survival in patients with lung cancer: a systematic review with meta-analysis
Junfang Zhang, Xuan Tang, Wenbo Zhang, Ying Xu, Heng Zhang, Yu Fan
International Journal of Obesity.2025; 49(1): 13. CrossRef - Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors
Fabrice N. Njotu, Jessica Pougoue Ketchemen, Hanan Babeker, Nikita Henning, Anjong F. Tikum, Emmanuel Nwangele, Alissar Monzer, Nava Hassani, Brian D. Gray, Koon Y. Pak, Emina E. Torlakovic, Maruti Uppalapati, Humphrey Fonge
European Journal of Nuclear Medicine and Molecular Imaging.2025; 52(4): 1305. CrossRef - Interactions and communications in lung tumour microenvironment: chemo/radiotherapy resistance mechanisms and therapeutic targets
Yuan Feng, Ying Jiang, Lin Yang, Danni Lu, Ning Li, Qun Zhang, Haiyan Yang, Huiyuan Qin, Jiaxin Zhang, Xinyun Gou, Feng Jiang
Journal of Drug Targeting.2025; 33(6): 817. CrossRef - The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment
Yanchao Luan, Chao Liang, Qingsong Han, Xueqin Zhou, Na Yang, li Zhao
BMC Cancer.2025;[Epub] CrossRef - Secretome and Proteome of Extracellular Vesicles Provide Protein Markers of Lung and Colorectal Cancer
Natalia Soloveva, Svetlana Novikova, Tatiana Farafonova, Olga Tikhonova, Victor Zgoda
International Journal of Molecular Sciences.2025; 26(3): 1016. CrossRef - Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer
Lu Zheng, Yanzhu Bian, Yujing Hu, Congna Tian, Xinchao Zhang, Shuheng Li, Xin Yang, Yanan Qin
Frontiers in Medicine.2025;[Epub] CrossRef - Artificial intelligence-assisted point-of-care devices for lung cancer
Xin Jie Keith Ng, Anis Salwa Mohd Khairuddin, Hai Chuan Liu, Thian Chee Loh, Jiunn Liang Tan, Sook Mei Khor, Bey Fen Leo
Clinica Chimica Acta.2025; 570: 120191. CrossRef - Genetic Navigation: A Narrative Review of XRCC1 Polymorphism Impact on Platinum-Based Chemotherapy Outcomes in NSCLC Patients
Lanny Permatasari, Nadiya Afifah, Maryam Ishmatullah, Ruri Intania, Eli Halimah, Melisa Barliana
Cancer Management and Research.2025; Volume 17: 383. CrossRef - Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study
Qi-An Wang, I-Lin Tsai, Chien-Yu Lin, Po-Lan Su, Chien-Chung Lin, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Cheng-Ta Yang, Chiao-En Wu
Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef - Ex-Vivo Drug-Sensitivity Testing to Predict Clinical Response in Non-Small Cell Lung Cancer and Pleural Mesothelioma: A Systematic Review and Narrative Synthesis
Jenny Zipprick, Enes Demir, Hanna Krynska, Sıla Köprülüoğlu, Katharina Strauß, Marcus Skribek, Rita Hutyra-Gram Ötvös, Annica K. B. Gad, Katalin Dobra
Cancers.2025; 17(6): 986. CrossRef - Defining long-term survivors in metastatic lung cancer: insights from a Delphi study in Spain
Enric Carcereny, Manuel Domine, Ana Laura Ortega Granados
Frontiers in Oncology.2025;[Epub] CrossRef - Genomics and the early diagnosis of lung cancer
Francesco Pepe, Tancredi Didier Bazan Russo, Valerio Gristina, Andrea Gottardo, Giulia Busuito, Giuliana Iannì, Gianluca Russo, Claudia Scimone, Lucia Palumbo, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Galvano, Viviana Bazan, Antonio Russo, Giancarl
Personalized Medicine.2025; 22(3): 161. CrossRef - Single-cell transcriptomics and machine learning unveil ferroptosis features in tumor-associated macrophages: Prognostic model and therapeutic strategies for lung adenocarcinoma
Ting Ji, Juanli Jiang, Xin Wang, Kai Yang, Shaojin Wang, Bin Pan
Frontiers in Pharmacology.2025;[Epub] CrossRef - Senescence-associated secretory phenotype in lung cancer: remodeling the tumor microenvironment for metastasis and immune suppression
Chen Chen, Ji Chen, Yanling Zhang, Qijun Zhang, Haixia Shi
Frontiers in Oncology.2025;[Epub] CrossRef - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Lazertinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Louis Fabio Jonathan Jusni, Eric Ricardo Yonatan, Nicolas Daniel Widjanarko, Rio Gusta Notario Besri
Hematology/Oncology and Stem Cell Therapy.2025; 18(2): 48. CrossRef - The predictive value of ferroptosis marker SLC7A11 in the prognosis of advanced non-small cell lung cancer patients
Shiqiang Wang, Xinlai Jin, Xuefei Yang, Zhidi Zhang
Clinical Biochemistry.2025; 138: 110961. CrossRef - p53 aberrant expression is pervasive in pleomorphic carcinomas of the lung and a sensitive diagnostic adjunct for biopsy specimens
Joshua Jing Xi Li, Chit Chow, Joanna Ka Man Ng, Ka Pang Chan, Molly Siu Ching Li, Ka-Fai To
Diagnostic Pathology.2025;[Epub] CrossRef - Diagnostic performance of artificial intelligence models for pulmonary nodule classification: a multi-model evaluation
Sarah K. Herber, Lukas Müller, Daniel Pinto dos Santos, Tobias Jorg, Fabio Souschek, Tobias Bäuerle, Sebastian Foersch, Christian Galata, Peter Mildenberger, Moritz C. Halfmann
European Radiology.2025; 36(1): 537. CrossRef - Small-Cell Lung Cancer Updates
Yunan Nie, Anne C. Chiang
Seminars in Respiratory and Critical Care Medicine.2025; 46(05): 467. CrossRef - A shape complementarity strategy based on NCA029 enables potent HsClpP agonists for the treatment of small cell lung carcinoma
Linjie Li, Baozhu Luo, Xudong Wang, Zhongyu Jian, Hong Liu, Bo Ren, Wenliang Qiao, Youfu Luo, Tao Yang
European Journal of Medicinal Chemistry.2025; 299: 118008. CrossRef - CLDN4 regulates cell proliferation in small cell lung cancer cells via SAA1 inhibition
Korehito Kashiwagi, Hanako Sato-Yazawa, Jun Ishii, Masami Iwamoto, Kakeru Kohno, Tadasuke Miyazawa, Tamotsu Kamimura, Shunsuke Miyata, Ruri Sugiyama, Hideki Chiba, Takuya Yazawa
Biochemical and Biophysical Research Communications.2025; 785: 152710. CrossRef - Autophagy inhibition enhances sensitivity of alpelisib in PI3K–mutated non-small cell lung cancer
Jinyoung Kim, Chandani Shrestha, Tae Woo Kim, Sang-Bin Lee, Gwangbin Lee, Dasom Jung, Min Hwang, Shinwon Kang, Hyung Soon Park, Hyunho Kim, Ho Jung An, Dongwoo Chae, Byoung Yong Shim, Jiyoon Kim
Biomedicine & Pharmacotherapy.2025; 192: 118620. CrossRef - Lung Cancer Management: A Comprehensive Review with Special Focus on Natural Remedies and Bioactive Compounds
Raj Shekhar, P. Muralidharan, Namrata Hallur, S. B. Puranik, Phatru Patel
Journal of Natural Remedies.2025; : 1989. CrossRef - Ferroptosis and non-coding RNAs in lung cancer: exploring molecular mechanisms and diagnostic/therapeutic implications
Hedong Xue, Melika Malek, Liangyu Li
Cancer Cell International.2025;[Epub] CrossRef - Association of Pre‐ and Postdiagnosis Physical Activity, Promotion and Maintenance With Lung Cancer Survival: A Nationwide Cohort Study
Yeon Wook Kim, Kyeong Im Kwak, A‐Reum Choi, Eung Joo Park, Brian J. Lee, Yeon Joo Lee, Choon‐Taek Lee
Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef - Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future
Gian Marco Leone, Grazia Scuderi, Paolo Fagone, Katia Mangano
International Journal of Molecular Sciences.2025; 26(22): 11055. CrossRef - Radiogenomic insights from a Portuguese lung cancer cohort: Foundations for predictive modeling
Inês Neves, Cláudia Freitas, Carolina Lemos, Hélder P. Oliveira, Venceslau Hespanhol, Manuela França, Tania Pereira
Measurement and Evaluations in Cancer Care.2025; 3: 100025. CrossRef - Hyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases
Yu-An Zheng, Ke-Cheng Chen, Pei-Ming Huang, Mong-Wei Lin, Shuenn-Wen Kuo, Jang-Ming Lee
Oncology.2025; 104(7): 733. CrossRef - Lung Cancer Outcomes in Vietnam: A 6-Year Retrospective Study
Khanh Toan Nguyen, Thi Huong Pham, Van Lam Ngo, Thi Thuy My Nguyen, Thi Dao Nguyen, Van Thanh Le, Van Nhat Nguyen, Thi Thanh Thuy Nguyen, Khanh Ha Nguyen, Thi Nhung Ngo, Thi Hai Yen Le, Thi Phuong Thao Nguyen, Thi Ha Phuong Nguyen, Thi Hong Anh Vo, Thi Th
Journal of Immunotherapy and Precision Oncology.2025; 8(4): 254. CrossRef - Spatial Dynamics of Tumor Cell Plasticity in Lung Adenocarcinoma Revealed by Region‐Specific Single Cell Transcriptomics
Anna A. Khozyainova, Maxim E. Menyailo, Vera G. Subrakova, Dmitry M. Loos, Pavel S. Iamshchikov, Anton A. Fedorov, Maria S. Tretyakova, Ustinia A. Bokova, Evgeny O. Rodionov, Sergey V. Miller, Evgeny B. Topolnitsky, Denis V. Piankov, Sergei A. Korostelev,
Genes, Chromosomes and Cancer.2025;[Epub] CrossRef - Inflammatory cytokine-associated cisplatin resistance in non-small cell lung cancer and re-sensitization through interleukin-6 receptor blockade
Gizem Calibasi-Kocal
World Journal of Clinical Oncology.2025;[Epub] CrossRef - Anti-cancer Effects of Sargassum micracanthum Extract on Non-small Cell Lung Cancer Cells
Hyun-Ji Park, Seon-Eun Park, Gyoo-Yong Chi, Yung-Hyun Choi, Shin-Hyung Park
Journal of Physiology & Pathology in Korean Medicine.2025; 39(5): 120. CrossRef - Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma
Jae Seok Lee, Eun Kyung Kim, Kyung A Kim, Hyo Sup Shim
Cancer Research and Treatment.2024; 56(1): 104. CrossRef - The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline Round
Alberto Antonicelli, Piergiorgio Muriana, Giovanni Favaro, Giuseppe Mangiameli, Ezio Lanza, Manuel Profili, Fabrizio Bianchi, Emanuela Fina, Giuseppe Ferrante, Simone Ghislandi, Daniela Pistillo, Giovanna Finocchiaro, Gianluigi Condorelli, Rosalba Lembo,
Cancers.2024; 16(2): 417. CrossRef - Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer
Hyeon Hwa Kim, Jae Cheol Lee, In-Jae Oh, Eun Young Kim, Seong Hoon Yoon, Shin Yup Lee, Min Ki Lee, Jeong Eun Lee, Chan Kwon Park, Kye Young Lee, Sung Yong Lee, Seung Joon Kim, Jun Hyeok Lim, Chang-min Choi
Cancers.2024; 16(3): 528. CrossRef - Lung Cancer Proteogenomics: Shaping the Future of Clinical Investigation
Theofanis Vavilis, Maria Louiza Petre, Giannis Vatsellas, Alexandra Ainatzoglou, Eleni Stamoula, Athanasios Sachinidis, Malamatenia Lamprinou, Ioannis Dardalas, Ioannis N. Vamvakaris, Ioannis Gkiozos, Konstantinos N. Syrigos, Athanasios K. Anagnostopoulos
Cancers.2024; 16(6): 1236. CrossRef - Survival analysis and gender differences in hypertrophic cardiomyopathy proband patients referred for genetic testing
Rebeca Lorca, María Salgado, Rut Álvarez-Velasco, Julián R. Reguro, Vanesa Alonso, Juan Gómez, Eliecer Coto, Elías Cuesta-Llavona, Eva Lopez-Negrete, Isaac Pascual, Pablo Avanzas, Maite Tome
International Journal of Cardiology.2024; 408: 132117. CrossRef - 18F-Fluorodeoxyglucose Positron Emission Tomography-Based Risk Score Model for Prediction of Five-Year Survival Outcome after Curative Resection of Non-Small-Cell Lung Cancer
Chae Hong Lim, Sang-Won Um, Hong Kwan Kim, Yong Soo Choi, Hong Ryul Pyo, Myung-Ju Ahn, Joon Young Choi
Cancers.2024; 16(14): 2525. CrossRef - Study Progress of Circulating miRNA for Predicting Metastasis in Non-Small Cell Lung Cancer
靖靖 丛
Advances in Clinical Medicine.2024; 14(07): 65. CrossRef - Toll-like Receptors: Key Players in Squamous Cell Carcinoma Progression
Jolanta Smok-Kalwat, Paulina Mertowska, Sebastian Mertowski, Stanisław Góźdź, Ewelina Grywalska
Journal of Clinical Medicine.2024; 13(15): 4531. CrossRef - Timing of Palliative Care Consultation Impacts End of Life Care Outcomes in Metastatic Non-Small Cell Lung Cancer
Cameron J. Oswalt, Morgan M. Nakatani, Jesse Troy, Steven Wolf, Susan C. Locke, Thomas W. LeBlanc
Journal of Pain and Symptom Management.2024; 68(4): e325. CrossRef - Enhanced Lung Cancer Detection Using a Combined Ratio of Antigen–Autoantibody Immune Complexes against CYFRA 21-1 and p53
Heyjin Kim, Jin Kyung Lee, Hye-Ryoun Kim, Young Jun Hong
Cancers.2024; 16(15): 2661. CrossRef - Discrimination of Lung Cancer and Benign Lung Diseases Using BALF Exosome DNA Methylation Profile
Chinbayar Batochir, In Ae Kim, Eun Ji Jo, Eun-Bi Kim, Hee Joung Kim, Jae Young Hur, Do Won Kim, Hee Kyung Park, Kye Young Lee
Cancers.2024; 16(15): 2765. CrossRef - The clinical significance of endoplasmic reticulum stress related genes in non-small cell lung cancer and analysis of single nucleotide polymorphism for CAV1
Shuang Li, Junting Chen, Baosen Zhou
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef - A Highly Sensitive Toluene Gas Sensor Based on Pd/PdO Decorated SnO2 Prepared by Electrospinning
Chengyi Gong, Meng Chen, Fei Song, Peisi Yin, Xin Zhao, Xiaoyu You, Huaian Fu, Shanshan Yu, Xingyu Liu, Kai Zhang, Yongqi Yang, Zhipeng Tang, Xiangmin Du, Jiacong Xu, Qiang Jing, Bo Liu
ACS Applied Electronic Materials.2024;[Epub] CrossRef - miR-137: a potential therapeutic target for lung cancer
Shuanshuan Liu, Yanyun Ruan, Xu Chen, Bao He, Qi Chen
Frontiers in Cell and Developmental Biology.2024;[Epub] CrossRef - Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer
Tianxing Hu, Jiali Huang, Rui Chen, Hui Zhang, Mai Liu, Renbing Wang, Wenyi Zhou, Dechun Huang, Mingkang Cao, Depeng Li, Zhiyu Li, Hongxi Wu, Jinlei Bian
European Journal of Medicinal Chemistry.2024; 280: 116952. CrossRef - CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Suet Kee Loo, Gabriel Sica, Xian Wang, Tingting Li, Luping Chen, Autumn Gaither-Davis, Yufei Huang, Timothy F. Burns, Laura P. Stabile, Shou-Jiang Gao
Cell & Bioscience.2024;[Epub] CrossRef - RETRACTED: Methylation modification is a poor prognostic factor in non-small cell lung Cancer and regulates the tumor microenvironment: mRNA molecular structure and function
Kai Yang, YuPing Yang, Lin Yu, Fan Yang, YuXin Xiang, Jun Zeng, Na Huang
International Journal of Biological Macromolecules.2024; 282: 137214. CrossRef - Impact of Postoperative Prolonged Air Leakage on Long-Term Pulmonary Function after Lobectomy for Lung Cancer
June Yeop Lee, Joonseok Lee, Varissara Javakijkarnjanakul, Beatrice Chia-Sui Shih, Woohyun Jung, Jae Hyun Jeon, Kwhanmien Kim, Sanghoon Jheon, Sukki Cho
Journal of Chest Surgery.2024; 57(6): 511. CrossRef - M1 macrophage-related prognostic model by combining bulk and single-cell transcriptomic data in NSCLC
Liu Zhe, Liu Fang, Petinrin Olutomilayo Olayemi, Toseef Muhammad, Chen Nanjun, Zhu Zhongxu, Wong Ka-Chun
Exploration of Medicine.2024;[Epub] CrossRef - Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring
Michele Tomanelli, Federica Guffanti, Giulia Vargiu, Edoardo Micotti, Mara Rigamonti, Francesca Tumiatti, Elisa Caiola, Mirko Marabese, Massimo Broggini
Frontiers in Oncology.2024;[Epub] CrossRef - Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection
Silvia D’Ambrosi, Stavros Giannoukakos, Mafalda Antunes-Ferreira, Carlos Pedraz-Valdunciel, Jillian W. P. Bracht, Nicolas Potie, Ana Gimenez-Capitan, Michael Hackenberg, Alberto Fernandez Hilario, Miguel A. Molina-Vila, Rafael Rosell, Thomas Würdinger, Da
International Journal of Molecular Sciences.2023; 24(5): 4881. CrossRef - Low diffusion capacity predicts poor prognosis in extensive stage small cell lung cancer: a single-center analysis of 10 years
Jee Seon Kim, Eun Ji Kim, Jong Geol Jang, Kyung Soo Hong, June Hong Ahn
Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7275. CrossRef - Prior treated tuberculosis and mortality risk in lung cancer
Kuang-Ming Liao, Chung-Shu Lee, Yu-Cih Wu, Chin-Chung Shu, Chung-Han Ho
Frontiers in Medicine.2023;[Epub] CrossRef - All-round counterattack to conquer lung cancer
Seung Hun Jang
Journal of the Korean Medical Association.2023; 66(3): 154. CrossRef - Metabolic profiles of lung adenocarcinoma via peripheral blood and diagnostic model construction
Kyung Soo Kim, Seok Whan Moon, Mi Hyung Moon, Kwan Yong Hyun, Seung Joon Kim, Young Koon Kim, Kwang Youl Kim, Dong Wook Jekarl, Eun-Jee Oh, Yonggoo Kim
Scientific Reports.2023;[Epub] CrossRef - STEMI in women. Life expectancy recovery after primary percutaneous coronary intervention
Marcel Almendárez, Rut Álvarez-Velasco, Pablo Avanzas, Alberto Alperi, Luis Gutiérrez, David Ledesma, Javier Martínez, Daniel Hernández-Vaquero, Rebeca Lorca, Luis Arboine, Cesar Morís, Isaac Pascual
Revista Española de Cardiología (English Edition).2023; 76(12): 1003. CrossRef - A Retrospective Analysis Comparing VATS Cost Discrepancies and Outcomes in Primary Lung Cancer vs. Second Primary Lung Cancer Patients
Bogdan Cosmin Tanase, Alin Ionut Burlacu, Claudiu Eduard Nistor, Teodor Horvat, Cristian Oancea, Monica Marc, Emanuela Tudorache, Tudor Mateescu, Diana Manolescu
Healthcare.2023; 11(12): 1745. CrossRef - IAMCEST en mujeres. Recuperación de la expectativa de vida tras la intervención coronaria percutánea
Marcel Almendárez, Rut Álvarez-Velasco, Pablo Avanzas, Alberto Alperi, Luis Gutiérrez, David Ledesma, Javier Martínez, Daniel Hernández-Vaquero, Rebeca Lorca, Luis Arboine, Cesar Morís, Isaac Pascual
Revista Española de Cardiología.2023; 76(12): 1003. CrossRef - Synthetic Tabular Data Based on Generative Adversarial Networks in Health Care: Generation and Validation Using the Divide-and-Conquer Strategy
Ha Ye Jin Kang, Erdenebileg Batbaatar, Dong-Woo Choi, Kui Son Choi, Minsam Ko, Kwang Sun Ryu
JMIR Medical Informatics.2023; 11: e47859. CrossRef - Exosomes in lung cancer metastasis, diagnosis, and immunologically relevant advances
Jianhua Zhao, Xiwen Li, Lele Liu, Zhen Zhu, Chunyan He
Frontiers in Immunology.2023;[Epub] CrossRef
- Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial
- 22,584 View
- 623 Download
- 97 Web of Science
- 82 Crossref
- Skin cancer
- Incidence and Survival Rates of Cutaneous Melanoma in South Korea Using Nationwide Health Insurance Claims Data
- TaeHo Kim, Siyeong Yoon, Dong-Eun Shin, Sang Cheol Lee, Jisu Oh, So-Young Lee, Do Kyung Kim, Segi Kim, Bosung Jung, Minsup Kim, Soonchul Lee
- Cancer Res Treat. 2022;54(3):937-949. Published online September 30, 2021
- DOI: https://doi.org/10.4143/crt.2021.871
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
Melanoma incidence is rising worldwide along with the associated personal and socioeconomic health expenditures. We investigated the incidence and survival-rate patterns of melanoma in South Korea using nationwide data.
Materials and Methods
This retrospective cohort study included patients with melanoma between 2004 and 2017, based on National Health Insurance (NHI) claims data in South Korea. The incidence, prevalence, and survival rate were analyzed along with baseline demographic characteristics. We collected solar irradiation dose (SID) and healthcare ranking score (HRS) according to the administrative district from the Korea Meteorological Administration and Korea Health Promotion Institute. The incidence and survival rates were assessed using Pearson's correlation, the Kaplan-Meier estimation, multiple linear regression, and multiple logistic regression methods.
Results
Twenty-five thousand, five hundred ninety-one patients with melanoma were diagnosed during the study period. The age-standardized incidence of melanoma steadily increased from 2004 to 2017 from 2.6 to 3.0/100,000/yr. The incidence of melanoma increased with significantly higher income (p < 0.05). The prevalence followed a similar pattern as the incidence. According to multivariate analysis, HRS significantly influenced the incidence of melanoma in high sun-exposed sites (p < 0.001). There was no significant change in annual mortality. Women had a higher 5-year survival rate than men (78.4% vs. 72.8%). Mortality by the administrative district was highly correlated with HRS.
Conclusion
The incidence of melanoma is increasing in South Korea. A low HRS is associated with both higher incidence and mortality. The findings of this study could be utilized as a guideline for treating melanoma patients. -
Citations
Citations to this article as recorded by- Association between Obesity and Melanoma Risk in an Asian Population: A Nationwide Cohort Study
Hye Yeon Koo, Kyungdo Han, Jihye Park, Jinhyung Jung, Seonghye Kim, Hyeonjin Cho, In Young Cho, Dong Wook Shin
Cancer Research and Treatment.2026; 58(2): 677. CrossRef - Nationwide Trends in Skin Cancer Incidence, Reconstructive Surgery Utilization, and Economic Burden in the Republic of Korea, 2011–2019
Joon Ho Song, Hyunsun Lim, Dae Hyun Lew, Yeo Reum Jeon
Journal of Craniofacial Surgery.2026; 37(5): 1143. CrossRef - Anatomic distribution and temporal trends of malignant melanoma among 960 cutaneous malignancies managed over 22 years at a tertiary plastic surgery department
Hye Mi Lee, Eun Jung Jang, Young Cheon Na
Archives of Craniofacial Surgery.2026; 27(2): 65. CrossRef - Adjuvant radiotherapy and skin cancer risk in breast cancer survivors: a nationwide cohort study in Korea
Je Hyun Chin, Dooreh Kim, Hye Sun Lee, Soyoung Jeon, Jin Ah Lee, Young Joo Lee, Soo Youn Bae, Woo-Chan Park, Jin Ho Song, Chang Ik Yoon
British Journal of Cancer.2026;[Epub] CrossRef - Scalp melanoma presents with greater Breslow thickness and higher metastatic burden: analysis of 105 Korean cutaneous head and neck melanoma patients
Hong Euy Kim, Jinkyeong Kim, Dong Hoon Lee, Hyun Jeong Shim, Sook Jung Yun
Melanoma Research.2026;[Epub] CrossRef - Risk of second primary malignancies among survivors of cutaneous melanoma: A nationwide population-based study in the Republic of Korea
Joon Min Jung, Do Hyung Kim, Ye-Jee Kim, Ik Jun Moon, Woo Jin Lee, Sung Eun Chang, Mi Woo Lee, Chong Hyun Won
Scientific Reports.2025;[Epub] CrossRef - The Association Between Melanoma and Autoimmune Diseases: A Nationwide Population‐Based Study in the Republic of Korea
Do Hyung Kim, Ye‐Jee Kim, Ik Jun Moon, Woo Jin Lee, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Joon Min Jung
The Journal of Dermatology.2025; 52(12): 1819. CrossRef - Incidence and survival rates of primary cutaneous malignancies in Korea, 1999–2019: A nationwide population‐based study
Soon‐Hyo Kwon, Sangmin Choi, Joung Soo Kim, Sang Seok Kim, Mihn‐Sook Jue, Soo Hong Seo, Jihye Park, Mi Ryung Roh, Je‐Ho Mun, Jun Young Kim, Jee Woong Choi, Ji Won Byun, Sanghyun Park, Min Sung Kim, Seok‐Jong Lee
The Journal of Dermatology.2024; 51(4): 532. CrossRef - The Effect of Interval Training and Urtica Dioica Hydroalcoholic Extract on some Growth and Immune Factors in C57 Rats with Melanoma Cancer
Maryam Firoozi, Alireza Barari, Asieh Abbassi Daloii, Hossein Abednatanzi
Complementary Medicine Journal.2024; 13(4): 44. CrossRef - Hellebrigenin induces apoptosis by triggering cellular inhibitor of apoptosis 1 and Jun N-terminal kinase pathway in melanoma cells
Mu-Kuei Shieu, Yi-Ching Chuang, Hsin-Yu Ho, Chia-Chieh Lin, Yu-Sheng Lo, Ming-Ju Hsieh
Dermatologica Sinica.2024; 42(1): 19. CrossRef - Analyses of Osteogenesis Imperfecta in South Korea Using the Nationwide Health Insurance Service Claim Data: A Propensity Score-Matched Study
Sin Hyung Park, Ho Yoon, Siyeong Yoon, Jaiwoo Chung, Jae-hyun Kim, Soonchul Lee
Calcified Tissue International.2024; 115(6): 915. CrossRef - Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea
Isaac Kim, Jisu Oh, Siyeoung Yoon, Man-Yong Han, Jaiwoo Chung, Younghoon Jung, Hyun-Il Lee, Soonchul Lee
Melanoma Research.2024; 34(6): 528. CrossRef - FOXN3 Regulates Autophagic Activity to Suppress Drug Resistance in Melanoma Cells
Yaqi Wang, Hui Su, Xiaopeng Wang, Chen Tu, Tong Xiao, Bincheng Ren, Shuang Wang
Clinical, Cosmetic and Investigational Dermatology.2024; Volume 17: 2505. CrossRef - The effects of exposure to solar radiation on human health
R. E. Neale, R. M. Lucas, S. N. Byrne, L. Hollestein, L. E. Rhodes, S. Yazar, A. R. Young, M. Berwick, R. A. Ireland, C. M. Olsen
Photochemical & Photobiological Sciences.2023; 22(5): 1011. CrossRef - Survival rates for invasive cutaneous malignant melanoma in South Korea in accordance with the Eighth edition AJCC Cancer Staging Manual: A retrospective single center study
Seon Hwa Lee, Gi Ung Ha, Hyun Ji Lee, Ho Yun Chung, Seung Huh, Dae-Lyong Ha, Kyung Duck Park, Yong Hyun Jang, Weon Ju Lee, Seok-Jong Lee, Jun Young Kim
Indian Journal of Dermatology, Venereology and Leprology.2023; 90: 163. CrossRef - Clinicopathological characteristics and prognosis of Merkel cell carcinoma: a single-center retrospective study in Korea
Ik Jun Moon, Hyungmin Na, Hye Soo Cho, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Woo Jin Lee
Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10065. CrossRef
- Association between Obesity and Melanoma Risk in an Asian Population: A Nationwide Cohort Study
- 14,174 View
- 236 Download
- 12 Web of Science
- 16 Crossref
- Gastrointestinal cancer
- First Course of treatment and Prognosis of Exocrine Pancreatic Cancer in Korea from 2006 to 2017
- Mee Joo Kang, Jiwon Lim, Sung-Sik Han, Hyeong Min Park, Sang-Jae Park, Young-Joo Won, Sun-Whe Kim
- Cancer Res Treat. 2022;54(1):208-217. Published online May 21, 2021
- DOI: https://doi.org/10.4143/crt.2021.421
-
Abstract
PDFPubReaderePub
- Purpose
Hospital-based clinical studies have limitations in holistic assessment of cancer treatment and prognosis, as they omit out-of-hospital patients including elderly individuals. This study aimed to investigate trends in initial treatment and corresponding prognosis of patients with exocrine pancreatic cancer (EPC) in Korea.
Materials and Methods
The Korea Central Cancer Registry data of patients with EPC from 2006 to 2017 were retrospectively reviewed. We defined the first course of treatment (FT) as the cancer-directed treatment administered within four months after cancer diagnosis according to Surveillance, Epidemiology, and End Results (SEER) program.
Results
Among 62,209 patients with EPC, localized and regional (LR) SEER stage; patients over 70 years old; and ductal adenocarcinoma excluding cystic or mucinous (DAC) accounted for 40.6%, 50.1%, and 95.9%, respectively. “No active treatment” (NT, 46.5%) was the most frequent, followed by non-surgical FT (28.7%) and surgical FT (22.0%). Among 25,198 patients with LR EPC, surgical FT increased (35.9% to 46.3%) and NT decreased (45.0% to 29.5%) from 2006 to 2017. The rate of surgical FT was inversely related to age (55.1% [< 70 years], 37.3% [70-79 years], 10.9% [≥ 80 years]). Five-year relative survival rates of LR DAC were higher after surgical FT than after NT in localized (46.1% vs. 12.9%) and regional stage (23.6% vs. 4.9%) from 2012 to 2017.
Conclusion
Less than half of overall patients with LR EPC underwent surgical FT, and this proportion decreased significantly in elderly individuals. Clinicians should focus attention on elderly patients with EPC to provide appropriate medical advice. -
Citations
Citations to this article as recorded by- Epidemiology of Gastric Cancer in Korea (1999–2022): Incidence, Survival, and 5-Year Conditional Relative Survival
Ki Bum Park, Mee Joo Kang, Johyun Ha, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Kyu-Won Jung, Han Hong Lee
Journal of Gastric Cancer.2026; 26(1): 4. CrossRef - Long-term conditional relative survival trends in extrahepatic bile duct cancer: insights from a population-based retrospective cohort study in a high-incidence Asian Country, 1999–2021
Mee Joo Kang, Johyun Ha, Sang-Jae Park, Hyeong Min Park, Kyu-Won Jung, Sung-Sik Han
International Journal of Surgery.2026; 112(4): 10010. CrossRef - Conditional Relative Survival of Gallbladder Cancer: A Population-Based Study in a High-Incidence Asian Country from 1999 to 2021
Mee Joo Kang, Johyun Ha, Sang-Jae Park, Hyeong Min Park, Kyu-Won Jung, Sung-Sik Han
Annals of Surgical Oncology.2025; 32(9): 6272. CrossRef - Incidence, mortality, and survival of gallbladder, extrahepatic bile duct, and pancreatic cancers in Korea: A population-based study from 1999 to 2022
Mee Joo Kang, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Kyu-Won Jung, Sang-Jae Park
Annals of Hepato-Biliary-Pancreatic Surgery.2025; 29(3): 209. CrossRef - Updates on incidence, mortality and survival of liver cancer using Korea central cancer registry database: 1999–2022
Sung Yeon Hong, Mee Joo Kang, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Bong-Wan Kim, Kyu-Won Jung
Annals of Hepato-Biliary-Pancreatic Surgery.2025; 29(4): 381. CrossRef - Conditional Relative Survival of Exocrine Pancreatic Cancer: A Population-Based Study
Mee Joo Kang, Johyun Ha, Hyeong Min Park, Sang-Jae Park, Kyu-Won Jung, Sung-Sik Han
Annals of Surgical Oncology.2024; 31(2): 1178. CrossRef - Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study
Sujeong Shin, Won Sohn, Yoosoo Chang, Yoosun Cho, Min‐Jung Kwon, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu
Hepatology Research.2024; 54(6): 551. CrossRef - Three-year follow-up study reveals improved survival rate in NSCLC patients underwent guideline-concordant diagnosis and treatment
Huijuan Mu, Xing Yang, Yanxia Li, Bingzheng Zhou, Li Liu, Minmin Zhang, Qihao Wang, Qian Chen, Lingjun Yan, Wei Sun, Guowei Pan
Frontiers in Oncology.2024;[Epub] CrossRef - Epidemiological trends and factors associated with survival in patients with medulloblastoma: A 45-year population-based retrospective study
Dongjie He, Yahui Yang, Peiwen Wu, Siying Zhu, Hao Chang, Chao Zhang, Qiuju Shao, Zongyan Yu
Journal of Clinical Neuroscience.2024; 126: 154. CrossRef - Surgical management for elderly patients with pancreatic cancer
Sun-Whe Kim
Annals of Surgical Treatment and Research.2023; 105(2): 63. CrossRef - Exocrine pancreatic cancer as a second primary malignancy: A population-based study
Mee Joo Kang, Jiwon Lim, Sung-Sik Han, Hyeong Min Park, Sung Chun Cho, Sang-Jae Park, Sun-Whe Kim, Young-Joo Won
Annals of Hepato-Biliary-Pancreatic Surgery.2023; 27(4): 415. CrossRef - Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study
Mee Joo Kang, Jiwon Lim, Sung-Sik Han, Hyeong Min Park, Sun-Whe Kim, Woo Jin Lee, Sang Myung Woo, Tae Hyun Kim, Young-Joo Won, Sang-Jae Park
Scientific Reports.2022;[Epub] CrossRef - Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea
Hyeong Min Park, Young-Joo Won, Mee Joo Kang, Sang-Jae Park, Sun-Whe Kim, Kyu-Won Jung, Sung-Sik Han
Journal of Korean Medical Science.2022;[Epub] CrossRef - Epidemiology of Gastric Cancer in Korea: Trends in Incidence and Survival Based on Korea Central Cancer Registry Data (1999–2019)
Sin Hye Park, Mee Joo Kang, E Hwa Yun, Kyu-Won Jung
Journal of Gastric Cancer.2022; 22(3): 160. CrossRef - Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019
Mee Joo Kang, E Hwa Yun, Kyu-Won Jung, Sang-Jae Park
Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 220. CrossRef - Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019
Sung Yeon Hong, Mee Joo Kang, Taegyu Kim, Kyu-Won Jung, Bong-Wan Kim
Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 211. CrossRef
- Epidemiology of Gastric Cancer in Korea (1999–2022): Incidence, Survival, and 5-Year Conditional Relative Survival
- 8,983 View
- 122 Download
- 15 Web of Science
- 16 Crossref
- Gynecologic Cancer
- Cervical Cancer in Women with Normal Papanicolaou Tests: A Korean Nationwide Cohort Study
- Miseon Kim, Hyeongsu Kim, Dong Hoon Suh, Yong Beom Kim
- Cancer Res Treat. 2021;53(3):813-818. Published online December 10, 2020
- DOI: https://doi.org/10.4143/crt.2020.826
-
Abstract
PDFPubReaderePub
- Purpose
This study aimed to evaluate the risk of cervical cancer diagnosed within 1 year after the last of multiple consecutive normal Papanicolau (Pap) tests.
Materials and Methods
The database of the National Health Insurance Service was used. We obtained Pap test data for 11,052,116 women aged 30-79 between 2007-2012. The cumulative incidence rates and 5-year overall survival rates of cervical cancer diagnosed within 1 year after the last normal Pap test were compared between women with one (N1), two (N2), and three consecutive normal Pap tests (N3). Women who did not receive a Pap test during the study period were assigned in the N0 group.
Results
The 1-year cumulative incidence rates of cervical cancer were 58.9, 24.6, 20.3, and 14.2 per 105 in the N0, N1, N2, and N3 groups, respectively. Compared to the N1 group, the risk of cervical cancer diagnosed within 1 year of the last normal Pap test decreased by 17% (relative risk [RR], 0.825; 95% confidence interval [CI], 0.716 to 0.951) in the N2 group and 42% (RR, 0.578; 95% CI, 0.480 to 0.695) in the N3 group. However, the 5-year survival rate in women diagnosed with cervical cancer within 1 year of the last normal Pap test in the N3 group was not higher than that of the N1 group (79.6% vs. 81.3%, p=0.706).
Conclusion
As normal Pap tests are consecutively repeated, cervical cancer risk significantly decreases. However, previous consecutive normal Pap tests are not associated with improving survival outcomes in women shortly diagnosed with cervical cancer after the last normal Pap test. -
Citations
Citations to this article as recorded by- Socioeconomic disparities in Papanicolaou test utilization in Western Iran
Bahare Safari-Faramani, Roya Safari-Faramani, Farid Najafi, Davoud Khorasani Zavareh, Ali Kazemi Karyani, Mitra Darbandi
BMC Public Health.2024;[Epub] CrossRef - Frequency shift Raman-based sensing of serum MicroRNA for ultrasensitive cervical cancer diagnosis
Jie Wang, Shenxiang Liu, Benfei Wei, Yulong Liu
Photodiagnosis and Photodynamic Therapy.2024; 46: 104105. CrossRef - Elevated risk of cervical cancer in elderly women with incident ulcerative colitis in South Korea
Jihoon Kim, Halim Jo, Min Chul Ha, Hyunil Kim, Jung Kuk Lee, Jae Hun Han, San-Hui Lee, Dae Ryong Kang, Su Young Kim, Hyun-Soo Kim, Hee Man Kim
Scientific Reports.2023;[Epub] CrossRef
- Socioeconomic disparities in Papanicolaou test utilization in Western Iran
- 8,165 View
- 130 Download
- 3 Web of Science
- 3 Crossref
- Central nervous system
- A Nationwide, Population-Based Epidemiology Study of Primary Central Nervous System Tumors in Korea, 2007-2016: A Comparison with United States Data
- Ho Kang, Sang Woo Song, Johyun Ha, Young-Joo Won, Chul-Kee Park, Heon Yoo, Kyu-Won Jung
- Cancer Res Treat. 2021;53(2):355-366. Published online October 7, 2020
- DOI: https://doi.org/10.4143/crt.2020.847
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
The purpose of this study was to determine the epidemiologic characteristics and survival of patients with primary brain and other central nervous system (CNS) tumors in Korea and to compare our findings with those from the United States.
Materials and Methods
We collected data on primary brain and CNS tumors diagnosed between 2007 and 2016 from the Korea Central Cancer Registry. The age-standardized incidence rates (ASRs) and 5-year relative survival rates (RSRs) were evaluated. We applied the classification and definitions of the Central Brain Tumor Registry of the United States to our analysis for direct comparison with United States data.
Results
A total of 115,050 primary brain and CNS tumors were identified, and the ASR of all tumors was 22.01 per 100,000 individuals, which was lower than the 23.41 in the United States. However, the ASR of malignant tumors was significantly lower herein (4.27) than in the United States (7.08). Meningeal tumors were the most common histologic group among all tumors (ASR, 8.32). The 5-year RSR of all primary brain and other CNS tumors was 86.4%, and that of all malignant tumors was 44.1%, which was higher than the 35.8% observed in the United States. Among malignant tumors, glioblastomas had the lowest 5-year RSR (12.1%).
Conclusion
In Korea, malignant brain and other CNS tumors have a lower incidence and better survival outcome. -
Citations
Citations to this article as recorded by- Ethnic Disparities in Incidence and Prognosis of Molecularly Defined Adult-Type Diffuse Glioma
Chongshun Zhao, Peiheng Ma, Xiaopeng Li, Yunsong Pan, Zhong Zhang, Zenghui Qian, Wei Zhang
JCO Oncology Practice.2026;[Epub] CrossRef - Incidence of primary central nervous system tumors across age groups and histological groups in Osaka, Japan, 2011–2020
Kenji Kishimoto, Kayo Nakata, Mizuki Shimadzu Kato, Toshiki Ikawa, Haruka Kudo, Yoko Iwaki, Yoshihiro Kuwabara, Toshitaka Morishima, Isao Miyashiro
Journal of Neuro-Oncology.2026;[Epub] CrossRef - Serum Metabolomic Signature of Gliomas in an Indian Cohort: Identification of Grade-Specific Alterations and Potential Biomarkers
Muhammad Khizar Mohiuddin, Sumit Thakar, Sai Sanwid Pradhan, Saiswaroop Rajaratnam, Sai Phalguna Kanikaram, Sujith Kumar Pulukool, Venketesh Sivaramakrishnan, Dilip Mohan
Neurology India.2026; 74(2): 234. CrossRef - Global patterns and trends in brain and central nervous system tumor incidence by histological subtype in 185 countries in 2022: a population-based study
Shaoyuan Lei, Chao Li, Jiajia Wang, Rongshou Zheng
International Journal of Surgery.2026; 112(3): 5904. CrossRef - Pineal region germ cell tumors with secondary glioblastoma: A case report of long-term survival using chemoradiotherapy combined with TTFields
Shaoqun Li, Mingyao Lai, Lian Chen, Yingying Zhou, Juan Li, Minting Ye, Ruyu Ai, LiChao Wang, Yangqiong Zhang, Linbo Cai
Neuro-Oncology Advances.2026;[Epub] CrossRef - Comparative Outcomes of Consolidation Strategies After R‐MVP Induction in Primary Diffuse Large B‐Cell Lymphoma of the Central Nervous System
Sang‐A Kim, Jung Sun Kim, Ji Yun Lee, Joo Ho Lee, Keun‐Yong Eom, Chul‐Kee Park, Chae‐Yong Kim, Dae Seog Heo, Jeong‐Ok Lee, Tae Min Kim
Cancer Medicine.2026;[Epub] CrossRef - Thirty-Five Years of the Korean Brain Tumor Society (1991–2026) : A Historical Review
Youngbeom Seo, Eui Hyun Kim, Shin-Hyuk Kang
Journal of Korean Neurosurgical Society.2026; 69(4): 657. CrossRef - Hospital-based descriptive epidemiology of intracranial meningiomas in Palestine: A retrospective study from a major referral center (2018–2023)
Mohammad Abuawad, Ahmad Rjoub, Yazan Dumaidi, Motaz Daraghma, Mohammad A. Nour, Wafaa Abu Zahra, Noor Issa, Ahmed Daqour, Abdulsalam Alkaiyat, S Rehan Ahmad
PLOS One.2026; 21(7): e0339114. CrossRef - Comparative analysis of hypofractionated short-course versus standard radiation therapy in elderly patients with glioblastoma: analysis of nationwide database
Yong Kyun Won, Eun Seog Kim, In Young Jo, Hyuk-jin Oh, Sang Mi Lee, Ik Dong Yoo, Sun-pyo Hong, Jeong Won Lee, Jin Ho Song, Nayoon Kang, Hong Seok Jang
Journal of Neuro-Oncology.2025; 171(2): 463. CrossRef - 18F-FET PET/CT can aid in diagnosing patients with indeterminate MRI findings for brain tumors: a prospective study
Sheng-Chieh Chan, Tsung-Lang Chiu, Shu-Hang Ng, Hung-Wen Kao, Sheng-Tzung Tsai, Shu-Hsin Liu
Annals of Nuclear Medicine.2025; 39(4): 342. CrossRef - Management and survival trends for diffuse gliomas diagnosed at a single neurooncology center in China during 2000 to 2020
Depei Li, Yinsheng Chen, Tang-Fai Wong, Qunying Yang, ChengCheng Guo, Xiaobing Jiang, Chao Ke, Xiangheng Zhang, Jing Zeng, Yanchun Lv, Shaoxiong Wu, Jian Wang, Ke Sai, Yonggao Mou, Zhongping Chen
Scientific Reports.2025;[Epub] CrossRef - Analysis of Overall Survival in High-Grade Glioma Patients Treated With Surgery and Adjuvant Therapy
Sakshi Priya Dewangan , Geeta S Narayanan, Kiran Kumar BR
Cureus.2025;[Epub] CrossRef - VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study
Chengcheng Guo, Qunying Yang, Meiling Deng, Xiaoling Qiu, Shaoxiong Wu, Xiaojing Du, Ke Sai, Ziyu Dai, Zhenghe Chen, Ji Zhang, Fuhua Lin, Chao Ke, Shaoyan Xi, Wanming Hu, Zhihuan Zhou, Jiawei Li, Xi Cao, Yixiang Liao, Yanchun Lv, Dennis Brown, John Langla
Discover Oncology.2025;[Epub] CrossRef - The Natural History and Treatment of Meningiomas: An Update
Arsene Daniel Nyalundja, Fabrice Mugisha, Claire Karekezi
Seminars in Neurology.2024; 44(01): 001. CrossRef - Gamma knife radiosurgery as primary management for intracranial meningioma identified as growing on serial imaging
Yeong Jin Kim, Kyung-Sub Moon, Sue Jee Park, Tae-Young Jung, In-Young Kim, Shin Jung
Medicine.2024; 103(5): e37082. CrossRef - Changes in the Epidemiologic Pattern of Primary CNS Tumors in Response to the Aging Population: An Updated Nationwide Cancer Registry Data in the Republic of Korea
Yoon Hwan Byun, Johyun Ha, Ho Kang, Chul-Kee Park, Kyu-Won Jung, Heon Yoo
JCO Global Oncology.2024;[Epub] CrossRef - Surgical indications and outcomes of the endoscopic endonasal approach for brain tumors in older adults in Korea: a retrospective study
Sun Mo Nam, Yoon Hwan Byun, Jung Hee Kim, Min-Sung Kim, Chul-Kee Park, Yong Hwy Kim
Journal of Korean Society of Geriatric Neurosurgery.2024; 20(1): 21. CrossRef - Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma: A Nationwide Population-Based Study
Yeonhu Lee, Eunyoung Lee, Tae Hoon Roh, Se-Hyuk Kim
Journal of Korean Medical Science.2024;[Epub] CrossRef - Survival After Newly-Diagnosed High-Grade Glioma Surgery: What Can We Learn From the French National Healthcare Database?
Charles Champeaux Depond, Luc Bauchet, Dahmane Elhairech, Philippe Tuppin, Vincent Jecko, Joconde Weller, Philippe Metellus
Brain Tumor Research and Treatment.2024; 12(3): 162. CrossRef - Optimal timing of chemoradiation after resection or biopsy of glioblastomas: a nationwide population-based study
Dongeun Lee, Eunyoung Lee, Tae Hoon Roh, Se-Hyuk Kim
BMC Cancer.2024;[Epub] CrossRef - Association between insomnia disorder and mortality among patients who underwent craniotomy for brain tumor resection: a South Korean nationwide cohort study
Hey-ran Choi, In-Ae Song, Hye Yoon Park, Tak Kyu Oh
Sleep and Breathing.2023; 27(1): 329. CrossRef - Fully Automated MRI Segmentation and Volumetric Measurement of Intracranial Meningioma Using Deep Learning
Ho Kang, Joseph Nathanael Witanto, Kevin Pratama, Doohee Lee, Kyu Sung Choi, Seung Hong Choi, Kyung‐Min Kim, Min‐Sung Kim, Jin Wook Kim, Yong Hwy Kim, Sang Joon Park, Chul‐Kee Park
Journal of Magnetic Resonance Imaging.2023; 57(3): 871. CrossRef - Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period
Peter Y M Woo, Stephen Yau, Tai-Chung Lam, Jenny K S Pu, Lai-Fung Li, Louisa C Y Lui, Danny T M Chan, Herbert H F Loong, Michael W Y Lee, Rebecca Yeung, Carol C H Kwok, Siu-Kie Au, Tze-Ching Tan, Amanda N C Kan, Tony K T Chan, Calvin H K Mak, Henry K F Ma
Neuro-Oncology Practice.2023; 10(1): 50. CrossRef - Paths of Evolution of Progressive Anaplastic Meningiomas: A Clinical and Molecular Pathology Study
Rina Di Bonaventura, Liverana Lauretti, Maurizio Martini, Tonia Cenci, Giuliano Di Monaco, Davide Palombi, Giovanni Maria Ceccarelli, Silvia Chiesa, Marco Gessi, Alessia Granitto, Alessio Albanese, Luigi Maria Larocca, Quintino Giorgio D’Alessandris, Robe
Journal of Personalized Medicine.2023; 13(2): 206. CrossRef - Intracranial Germinomas: Diagnosis, Pathogenesis, Clinical Presentation, and Management
Natalia Kremenevski, Michael Buchfelder, Nirjhar Hore
Current Oncology Reports.2023; 25(7): 765. CrossRef - Decreased income, unemployment, and disability after craniotomy for brain tumor removal: a South Korean nationwide cohort study
Tak Kyu Oh, In-Ae Song, Ji-Eyon Kwon, Solyi Lee, Hey-Ran Choi, Young-Tae Jeon
Supportive Care in Cancer.2022; 30(2): 1663. CrossRef - Association between surgical volume and outcomes after craniotomy for brain tumor removal: A South Korean nationwide cohort study
Hey-ran Choi, In-Ae Song, Tak Kyu Oh
Journal of Clinical Neuroscience.2022; 100: 75. CrossRef - The comparative burden of brain and central nervous system cancers from 1990 to 2019 between China and the United States and predicting the future burden
Jiajia Huang, Hanmei Li, Hualing Yan, Fen-Xiang Li, Mai Tang, Da-Lin Lu
Frontiers in Public Health.2022;[Epub] CrossRef - Anaplastic Meningioma: Clinical Characteristics, Prognostic Factors and Survival Outcome
Dong Ok Seo, Sang Woo Song, Young-Hoon Kim, Chang-Ki Hong, Jeong Hoon Kim
Brain Tumor Research and Treatment.2022; 10(4): 244. CrossRef - Classification and Diagnosis of Adult Glioma: A Scoping Review
Yoon Hwan Byun, Chul-Kee Park
Brain & Neurorehabilitation.2022;[Epub] CrossRef - The epidemiology series of brain-related disorders in Mongolia: nationwide registry-based epidemiological study on CNS tumours in Mongolia, 2015–2019
Tuvshingerel Sandagdorj, Undarmaa Tudev, Otgonbold Jamiyandorj, Takakazu Oka, Battuvshin Lkhagvasuren
Journal of Integrative Neuroscience.2022;[Epub] CrossRef - Depression and mortality after craniotomy for brain tumor removal: A Nationwide cohort study in South Korea
Tak Kyu Oh, In-Ae Song, Hye Yoon Park, Young-Tae Jeon
Journal of Affective Disorders.2021; 295: 291. CrossRef
- Ethnic Disparities in Incidence and Prognosis of Molecularly Defined Adult-Type Diffuse Glioma
- 12,302 View
- 254 Download
- 32 Crossref
- Survival of Cancer Patients in Northeast China: Analysis of Sampled Cancers from Population-Based Cancer Registries
- Yanxia Li, Liya Yu, Jun Na, Shuang Li, Li Liu, Huijuan Mu, Xuanjuan Bi, Xiaoxia An, Xun Li, Wen Dong, Guowei Pan
- Cancer Res Treat. 2017;49(4):1106-1113. Published online February 2, 2017
- DOI: https://doi.org/10.4143/crt.2016.613
-
Abstract
PDFPubReaderePub
- Purpose
The cancer survival was characterized by following up sampled subgroups of cancer cases from three population-based cancer registries in Northeast China.
Materials and Methods
Survival analysis was used to analyze 6,871 patients, who had one of the 21 most common cancers based on sampling from the population-based cancer registries of three cities in Liaoning Province. All patients were diagnosed between 2000 and 2002 and were followed up to the end of 2007 by active and passive methods. The 5-year age standardized relative survival rates (ASRS) were estimated for all cancers combined and each of the 21 individual cancers.
Results
The survival status was traced for 80.8% of 8,506 sampled cancer cases. The 5-year ASRS for all 21 cancers combined was 41.5% (95% confidence interval, 40.3 to 42.7), the highest ASRS was observed for thyroid cancer (85.2%), breast cancer (78.9%), uterine corpus cancer (75.9%), and urinary bladder cancer (70.2%); the lowest 5-year ASRS was noted in pancreatic cancer (8.8%), liver cancer (11.0%), esophageal cancer (18.8), and lung cancer (19.6%). The cancer survival rates in Liaoning cities were similar to those of urban areas in mainland China, but significantly lower than those in Hong Kong, Korea, and Japan.
Conclusion
The strikingly poor cancer survival rates in three cities of Liaoning Province and in other places in China highlight the need for urgent investment in cancer prevention, early detection, and standardized and centralized treatment. -
Citations
Citations to this article as recorded by- A global review and perspective on prostate cancer survival: findings from survival studies of cancer registration data
Yuxin Zhou, Yixin Zou, Qiuming Shen, Zhuoying Li, Yuting Tan, Honglan Li, Yongbing Xiang
Journal of the National Cancer Center.2026; 6(2): 175. CrossRef - Five-year survival rate of kidney cancer (localized renal cell carcinoma) in the Asia: A systematic review and meta-analysis
Hamed Delam, Reza Zare, Zahra Keshtkaran, Ahmadreza Eidi, Mohammad Sadegh Moradi Sarcheshmeh, Alireza Shahedi, Soheil Hassanipour, Meghdad Abdollahpour-Alitappeh, Ehsan Amini-Salehi
Medicine.2025; 104(34): e43867. CrossRef - Global characteristics of pancreatic cancer survival: a comprehensive overview of survival analysis from cancer registration data
Jun Chen, Yu-Xuan Xiao, Zhuo-Ying Li, Yi-Xin Zou, Xiao-Hui Zhou, Wei Zhang, Hong-Lan Li, Qun Xu, Yong-Bing Xiang
Journal of Pancreatology.2025; 8(4): 307. CrossRef - Cancer Survival Trends in Southeastern China, 2011–2021: A Population-Based Study
Yan Zhou, Yeying Wen, Zhisheng Xiang, Jingyu Ma, Yongtian Lin, Yongying Huang, Chuanben Chen
Clinical Epidemiology.2024; Volume 16: 45. CrossRef - Identification of m6a-related signature genes in esophageal squamous cell carcinoma by machine learning method
Qi-Xin Shang, Wei-Li Kong, Wen-Hua Huang, Xin Xiao, Wei-Peng Hu, Yu-Shang Yang, Hanlu Zhang, Lin Yang, Yong Yuan, Long-Qi Chen
Frontiers in Genetics.2023;[Epub] CrossRef - Health-Related Quality of Life and Thyroid Cancer-Specific Symptoms in Patients Treated for Differentiated Thyroid Cancer: A Single-Center Cross-Sectional Survey from Mainland China
Changlian Chen, Jiayan Cao, Yueyang Wang, Xuya Han, Yaju Zhang, Shumei Zhuang
Thyroid®.2023; 33(4): 474. CrossRef - Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study
Soheil Hassanipour, Reza Zare, Alireza Shahedi, Hamed Delam
Endocrine.2023; 82(2): 237. CrossRef - Trends of stomach cancer survival: A systematic review of survival rates from population‐based cancer registration
Jia Yi Tuo, Jing Hao Bi, Hui Yun Yuan, Yu Fei Jiang, Xiao Wei Ji, Hong Lan Li, Yong Bing Xiang
Journal of Digestive Diseases.2022; 23(1): 22. CrossRef - Research Progress in Immunotherapy of Esophageal Squamous Carcinoma
彩耘 李
Advances in Clinical Medicine.2022; 12(01): 545. CrossRef - FOXD3 and GAB2 as a pair of rivals antagonistically control hepatocellular carcinogenesis
Ruimin Liu, Yan Sun, Shuai Chen, Yun Hong, Zhongxian Lu
The FEBS Journal.2022; 289(15): 4536. CrossRef - Current status of premature mortality from four non-communicable diseases and progress towards the Sustainable Development Goal target 3.4: a population-based study in northeast China, 2004–2017
Li Liu, Yanxia Li, Junmin Song, Qian Chen, Shuang Li, Huijuan Mu, Jun Na, Rui Zhang, Liya Yu, Wei Sun, Guowei Pan
BMC Public Health.2021;[Epub] CrossRef - Utility of Circulating Tumor Cells for Detection of Early-Stage Luminal A Breast Cancer
Yang Zhang, Ji Qi, Jianyi Li, Shi Jia, Yitong Wang, Qiang Sun, Ye Kang, Yushi Liu, Yanan Cao, Jiaxin Yu
The American Journal of the Medical Sciences.2020; 360(5): 543. CrossRef - Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade
Jianjun Yang, Xiguang Liu, Sai Cao, Xiaoying Dong, Shuan Rao, Kaican Cai
Frontiers in Oncology.2020;[Epub] CrossRef - Cancer survival in Cixian of China, 2003–2013: a population‐based study
Dongfang Li, Daojuan Li, Guohui Song, Di Liang, Chao Chen, Yachen Zhang, Zhaoyu Gao, Yutong He
Cancer Medicine.2018; 7(4): 1537. CrossRef - Dosimetric comparison between helical tomotherapy and intensity‐modulated radiotherapy for esophageal carcinoma
Qing Gu, Xiao‐jing Lai, Shuang‐yan Yang, Wei Feng, Xiao Lin, Xiao‐fu Yu, Xiao Zheng
Precision Radiation Oncology.2017; 1(3): 88. CrossRef
- A global review and perspective on prostate cancer survival: findings from survival studies of cancer registration data
- 25,541 View
- 202 Download
- 17 Web of Science
- 15 Crossref
- Clinical Results of Chemotherapy based Treatment in Retinoblastoma Patients: A Single Center Experience
- Hyery Kim, Ji Won Lee, Hyoung Jin Kang, Hyeon Jin Park, Yoon Yi Kim, Hee Young Shin, Young Suk Yu, Il Han Kim, Hyo Seop Ahn
- Cancer Res Treat. 2008;40(4):164-171. Published online December 31, 2008
- DOI: https://doi.org/10.4143/crt.2008.40.4.164
-
Abstract
PDFPubReaderePub
Purpose Retinoblastoma is the most common intraocular malignancy in children. Since the 1990s, chemotherapy was indicated for intraocluar disease to reduce the frequency of enucleation and spare the complications associated with external beam radiation. In this study, we analyzed treatment results of retinoblastoma in our institute.
Materials and Methods Datas from children diagnosed with retinoblastoma and treated at Seoul National University Children's Hospital between 1986 and 2008 were analyzed retrospectively. We utilized cyclophosphamide, vincristine, adriamycin, and methotrexate (CVAM) for OPD-based adjuvant chemotherapy. From 1990, primary chemotherapy was administered to patients with intraocular disease for eyeball-saving and patients received a combination of etoposide, vincristine, cisplatin (or ifosfamide) as a moderately intensive regimen, or a combination of cisplatin, doxorubicin, etoposide, and cycophosphamide (CDEC) as a highly intensive regimen.
Results One hundred eighteen children were analyzed. There were 68 unilateral and 50 bilateral diseases. The median age at diagnosis was 1 year and Reese-Ellsworth stage V was the most common stage at the time of diagnosis. All patients were treated by chemotherapy-based multimodality methods, and primary chemotherapy was administered to 80 patients. The 10-year overall and event-free survival rate of all patients were 93.9% and 91.6%, respectively. Two patients who died were in the CDEC regimen group, but there was no significant statistical difference in survival rates by chemotherapy regimens. Fifty-six of 114 eyeballs were saved after primary chemotherapy-based treatment, and the eyeball-saving rate was 49.1%. Six patients relapsed after enucleation and 2 patients were treated successfully after autologous PBSCT. Osteosarcoma occurred in 2 patients as a secondary malignancy, and facial asymmetry after radiotherapy was the most common long-term sequelae.
Conclusions In this study, the overall and event-free survival rates of retinoblastoma were satisfactory and eye-saving was possible with primary chemotherapy. Development of new chemotherapeutic regimens and a team approach are necessary to improve the eyeball-saving rate.
-
Citations
Citations to this article as recorded by- Systematic review of facial deformation following paediatric head and neck radiation therapy: A call for standardised outcome assessment and dose–response evidence
Angela Davey, Lucy Siew Chen Davies, Shermaine Pan, Koen B. Krommenhoek, Emma Foster-Thomas, Nanouschka H. Maagdenberg, Bernadette Brennan, Frances Charlwood, Simona Gaito, Mark N. Gaze, Callum Gillies, Love Goyal, Cynthia L. Eccles, Daniel J. Indelicato,
Radiotherapy and Oncology.2026; 219: 111448. CrossRef - The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases
Chiara Crotti, Nicola Ughi, Emanuela Beretta, Antonio Luca Brucato, Greta Carrara, Maria Sole Chimenti, Paola Conigliaro, Francesca Crisafulli, Giovanna Cuomo, Emma Di Poi, Khadija El Auofy, Micaela Fredi, Maria Chiara Gerardi, Maria Gerosa, Ariela Hoxa,
Reumatismo.2025;[Epub] CrossRef - The Efficacy of Alternate Systemic Intravenous Chemotherapy and Intra-arterial Chemotherapy Approach for Eye Globe Salvage in Retinoblastoma
Jung Woo Han, Christopher Seungkyu Lee, Seung Min Hahn, Won Kee Ahn, Hyo Sun Kim, Hyeseon Yun, Sung Chul Lee, Byung Moon Kim, Dong Joon Kim, Chuhl Joo Lyu
Cancer Research and Treatment.2023; 55(1): 270. CrossRef - Global retinoblastoma survival and globe preservation: a systematic review and meta-analysis of associations with socioeconomic and health-care factors
Emily S Wong, Richard W Choy, Yuzhou Zhang, Wai Kit Chu, Li Jia Chen, Chi Pui Pang, Jason C Yam
The Lancet Global Health.2022; 10(3): e380. CrossRef - Twenty-Year Retrospective Study of Post-Enucleation Chemotherapy in High-Risk Patients with Unilateral Retinoblastoma
Yoon Sunwoo, Jung Yoon Choi, Hyun Jin Park, Bo Kyung Kim, Kyung Taek Hong, Sang In Khwarg, Jaemoon Koh, Sung-Hye Park, Dong Hyun Jo, Jeong Hun Kim, Jung-Eun Cheon, Hyoung Jin Kang
Children.2022; 9(12): 1983. CrossRef - Development of New Solitary Retinoblastoma Tumors during and after Chemotherapy
Won Jong Choi, Dong Hyun Jo, Hyoung Jin Kang, Hee Young Shin, Young Suk Yu, Jeong Hun Kim
Korean Journal of Ophthalmology.2021; 35(1): 73. CrossRef - Outcomes of pediatric retinoblastoma treated with ICEV regimen: A single-center study
Jassada Buaboonnam, Nattee Narkbunnam, Nassawee Vathana, Chayamon Takpradit, Kamon Phuakpet, Bunchoo Pongtanakul, Sasima Tongsai, La-Ongsri Atchaneeyasakul, Kleebsabai Sanpakit
Pediatric Hematology and Oncology.2019; 36(2): 73. CrossRef - Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
Francis L. Munier, Maja Beck-Popovic, Guillermo L. Chantada, David Cobrinik, Tero T. Kivelä, Dietmar Lohmann, Philippe Maeder, Annette C. Moll, Angel Montero Carcaboso, Alexandre Moulin, Paula Schaiquevich, Ciara Bergin, Paul J. Dyson, Susan Houghton, Fra
Progress in Retinal and Eye Research.2019; 73: 100764. CrossRef - Outcomes of Proton Beam Radiation Therapy for Retinoblastoma With Vitreous Seeds
Eun Hye Jung, Jeong Hun Kim, Joo Young Kim, Dong Hyun Jo, Young Suk Yu
Journal of Pediatric Hematology/Oncology.2018; 40(8): 569. CrossRef - Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress
Zeren Shen, Jinjin Shao, Jiabin Dai, Yuchen Lin, Xiaochun Yang, Jian Ma, Qiaojun He, Bo Yang, Ke Yao, Peihua Luo
Toxicology Reports.2016; 3: 78. CrossRef - Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma
Seung Min Hahn, Hyo Sun Kim, Dong Joon Kim, Sung Chul Lee, Chuhl Joo Lyu, Jung Woo Han
Pediatric Hematology and Oncology.2016; 33(1): 74. CrossRef - Diagnosis & Treatment of Retinoblastoma: Current Review
Heewon Chueh
Clinical Pediatric Hematology-Oncology.2015; 22(1): 38. CrossRef - High‐dose chemotherapy with autologous stem cell rescue for treatment of retinoblastoma: Report of five cases
Désirée Caselli, Angela Tamburini, Agostino La Torre, Liliana Pollazzi, Veronica Tintori, Franco Bambi, Roberto Caputo, Maurizio Aricò
Pediatric Transplantation.2014; 18(6): 631. CrossRef - Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments
Carlo Venturi, Sandra Bracco, Alfonso Cerase, Samuele Cioni, Paolo Galluzzi, Paola Gennari, Ignazio M. Vallone, Rebecca Tinturini, Cesare Vittori, Sonia De Francesco, Mauro Caini, Alfonso D’Ambrosio, Paolo Toti, Alessandra Renieri, Theodora Hadjistilianou
Acta Ophthalmologica.2013; 91(4): 335. CrossRef - Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma
Aman Khurana, Christina A. Eisenhut, Wenshuai Wan, Katayoon B. Ebrahimi, Chirag Patel, Joan M. O’Brien, Kristen Yeom, Heike E. Daldrup-Link
European Radiology.2013; 23(5): 1271. CrossRef - Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells
HYUN BEOM SONG, HYOUNG-OH JUN, JIN HYOUNG KIM, YOUNG SUK YU, KYU-WON KIM, BON HONG MIN, JEONG HUN KIM
Oncology Reports.2013; 30(6): 2713. CrossRef - Combined Treatment with an Oncolytic Adenovirus and Antitumor Activity of Vincristine against Retinoblastoma Cells
Xin Song, Haibo Wang, Renbing Jia, Biyun Cun, Xiaoping Zhao, Yixiong Zhou, Xiaofang Xu, Guanxiang Qian, Shengfang Ge, Xianqun Fan
International Journal of Molecular Sciences.2012; 13(9): 10736. CrossRef - Long Term Follow-up Results of External Beam Radiotherapy as Primary Treatment for Retinoblastoma
Sang Yul Choi, Mi-Sook Kim, SungYul Yoo, ChulKoo Cho, YoungHoon Ji, KumBae Kim, YoungSeok Seo, Kyung Duk Park, JunAh Lee, Tai-Won Lee
Journal of Korean Medical Science.2010; 25(4): 546. CrossRef
- Systematic review of facial deformation following paediatric head and neck radiation therapy: A call for standardised outcome assessment and dose–response evidence
- 14,829 View
- 86 Download
- 18 Crossref
- Occludin Expression in Brain Tumors and its Relevance to Peritumoral Edema and Survival
- Min-Woo Park, Choong-Hyun Kim, Jin-Hwan Cheong, Koang-Hum Bak, Jae-Min Kim, Suck-Jun Oh
- Cancer Res Treat. 2006;38(3):139-143. Published online June 30, 2006
- DOI: https://doi.org/10.4143/crt.2006.38.3.139
-
Abstract
PDFPubReaderePub
Purpose Peritumoral brain edema (PTBE) is a serious causative factor that contributes the morbidity or mortality of brain tumors. The development of PTBE is influenced by many factors, including such tight junction proteins as occludin. We evaluated the PTBE volume and survival time with respect to the occludin expression in various pathological types of brain tumors.
Materials and Methods Fresh-frozen specimens from sixty patients who had brain tumors were obtained during surgery and the tumors were confirmed pathologically. The occludin expression was investigated by Western blot analysis. The PTBE volume was measured by using preoperative magnetic resonance (MR) imaging, and the survival time in each patient was estimated retrospectively.
Results Occludin was detected in 41 (68.3%) of the cases with brain tumors and it was not expressed in the other 19 (31.7%) cases. Although the lowest expression was revealed in high-grade gliomas, its expression was variable according to the pathology of the brain tumors (p>0.05). The difference of PTBE volume between occludin-positive and negative brain tumors was statistically significant (2072.46±328.73 mm3 vs. 7452.42±1504.19 mm3, respectively, p=0.002). The mean survival time was longer in the occludin-positive tumor group than in the occludin-negative group (38.63±1.57 months vs. 26.16±3.83 months, respectively; p=0.016).
Conclusions This study suggests that the occludin expression is highly correlated to the development of PTBE in brain tumors and it might be a prognostic indicator for patient survival.
-
Citations
Citations to this article as recorded by- Occludin-mediated barrier dysfunction and its role in cardiovascular and cerebrovascular pathogenesis
Wei Xu, Tongzhang Xu, Huang Long, Qin Jiang, Weifang Liao
Frontiers in Cardiovascular Medicine.2026;[Epub] CrossRef - Tight junction proteins in glial tumors development and progression
Jakub Moskal, Slawomir Michalak
Frontiers in Cellular Neuroscience.2025;[Epub] CrossRef - Impact of pre-existing neuroendocrine tumors on brain tissue compliance following intracerebral hemorrhage in old spontaneously hypertensive rats
Anna C.J. Kalisvaart, Frederick Colbourne
Brain Hemorrhages.2025; 6(6): 285. CrossRef - Lipid-Based Nanocarriers for Neurological Disorders: A Review of the State-of-the-Art and Therapeutic Success to Date
Bwalya Angel Witika, Madan Sai Poka, Patrick Hulisani Demana, Scott Kaba Matafwali, Siyabonga Melamane, Sandile Maswazi Malungelo Khamanga, Pedzisai Anotida Makoni
Pharmaceutics.2022; 14(4): 836. CrossRef - Blood-Brain Barrier Alterations and Edema Formation in Different Brain Mass Lesions
Peter Solar, Michal Hendrych, Martin Barak, Hana Valekova, Marketa Hermanova, Radim Jancalek
Frontiers in Cellular Neuroscience.2022;[Epub] CrossRef - Evaluation of AQP4/TRPV4 Channel Co-expression, Microvessel Density, and its Association with Peritumoral Brain Edema in Intracranial Meningiomas
Konstantinos Faropoulos, Afroditi Polia, Chrisi Tsakona, Eleanna Pitaraki, Athanasia Moutafidi, George Gatzounis, Martha Assimakopoulou
Journal of Molecular Neuroscience.2021; 71(9): 1786. CrossRef - Peripheral Blood Occludin Level as a Biomarker for Perioperative Cerebral Edema in Patients with Brain Tumors
Shuhai Shi, Jingli Cheng, Chunyang Zhang, Tao Liang, Yunxin Zhang, Yongxing Sun, Ying Zhao, Weili Li, Baoguo Wang
Disease Markers.2020; 2020: 1. CrossRef - Intracerebral GM-CSF contributes to transendothelial monocyte migration in APP/PS1 Alzheimer’s disease mice
De S Shang, Yi M Yang, Hu Zhang, Li Tian, Jiu S Jiang, Yan B Dong, Ke Zhang, Bo Li, Wei D Zhao, Wen G Fang, Yu H Chen
Journal of Cerebral Blood Flow & Metabolism.2016; 36(11): 1978. CrossRef - Abnormal expression of an ADAR2 alternative splicing variant in gliomas downregulates adenosine-to-inosine RNA editing
Jun Wei, Zhaohui Li, Chao Du, Bin Qi, Xingli Zhao, Liping Wang, Lirong Bi, Guan Wang, Xuan Zhang, Xiaoyun Su, Yuzhuo Pan, Yu Tian
Acta Neurochirurgica.2014; 156(6): 1135. CrossRef - Evaluation of mast cells and hypoxia inducible factor-1 expression in meningiomas of various grades in correlation with peritumoral brain edema
Joanna Reszec, Adam Hermanowicz, Robert Rutkowski, Piotr Bernaczyk, Zenon Mariak, Lech Chyczewski
Journal of Neuro-Oncology.2013; 115(1): 119. CrossRef - Involvement of PI3K and ROCK signaling pathways in migration of bone marrow-derived mesenchymal stem cells through human brain microvascular endothelial cell monolayers
Mei-Na Lin, De-Shu Shang, Wei Sun, Bo Li, Xin Xu, Wen-Gang Fang, Wei-Dong Zhao, Liu Cao, Yu-Hua Chen
Brain Research.2013; 1513: 1. CrossRef
- Occludin-mediated barrier dysfunction and its role in cardiovascular and cerebrovascular pathogenesis
- 10,741 View
- 57 Download
- 11 Crossref
- Relationship between Pre-treatment Serum SCC (squamous cell carcinoma) Antigen, Cyfra 21-1 Levels, and Survival in Squamous Cell Carcinoma of the Uterine Cervix
- Ki-Hong Chang, Hee-Sug Ryu, Suk-Joon Chang, Young-Ji Byun, Jung-Pil Lee
- Cancer Res Treat. 2005;37(5):302-306. Published online October 31, 2005
- DOI: https://doi.org/10.4143/crt.2005.37.5.302
-
Abstract
PDFPubReaderePub
Purpose To determine the relationship between pretreatment serum squamous cell carcinoma (SCC) antigen and Cyfra 21-1 levels, and survival in patients with invasive squamous cell carcinoma of the cervix.
Materials and Methods One hundred and one cervical squamous cell carcinoma patients were included. Pre-treatment levels of serum SCC antigen and Cyfra 21-1 were measured, with a 5 year minimum follow up. Thirty two recurrent disease (RD) patients were compared to 99 non-recurrent disease (NRD) patients with respect to tumor markers, FIGO stage, lesion size, lymph node status, and parametrial involvement.
Results Pre-treatment serum SCC antigen and Cyfra 21-1 levels were significantly higher in the RD group (p<0.001). Combined serum SCC antigen and Cyfra 21-1 levels showed higher sensitivity for prediction of recurrence (90.6%). Pre-treatment SCC antigen and Cyfra 21-1 levels showed correlation with high FIGO stage, large lesion size, lymph node status, and parametrial involvement (p<0.001). Normal pre-treatment levels of SCC antigen and Cyfra 21-1 showed a 5-year survival rate of 93% and 90% respectively, while elevated levels showed significantly decreased survival rate of 63% and 59%, respectively (p<0.001). Odd ratio for cumulative survival rates were 6.87 for SCC antigen, and 5.07 for Cyfra 21-1 (p<0.001).
Conclusion Initial pre-treatment levels of serum SCC antigen and Cyfra 21-1 are closely related to FIGO stage, lesion size, lymph node and parametrial involvement in patients with squamous cell carcinoma of the cervix. Also, these markers may be of help to predicting recurrent disease and survival rates.
- 10,659 View
- 70 Download
Editorial
- Molecular Markers in Gastric Cancer: Can They Predict Prognosis?
- Seok Jin Kim, Yeul Hong Kim
- Cancer Res Treat. 2003;35(1):1-2. Published online February 28, 2003
- DOI: https://doi.org/10.4143/crt.2003.35.1.1
-
Abstract
PDF
- No abstract available.
-
Citations
Citations to this article as recorded by- Nuclear Factor-κB Activation Correlates with Better Prognosis and Akt Activation in Human Gastric Cancer
Byung Lan Lee, Hye Seung Lee, Jieun Jung, Sung Jin Cho, Hee-Yong Chung, Woo Ho Kim, Young-Woo Jin, Chong Soon Kim, Seon Young Nam
Clinical Cancer Research.2005; 11(7): 2518. CrossRef
- Nuclear Factor-κB Activation Correlates with Better Prognosis and Akt Activation in Human Gastric Cancer
- 4,466 View
- 20 Download
- 1 Crossref
Original Articles
- Expression of G1/S Phase Checkpoint Proteins in Breast Carcinoma: Relationship to Clinicopathologic Factors andSurvival Rate
- Mi Ja Lee
- Cancer Res Treat. 2002;34(4):268-273. Published online August 31, 2002
- DOI: https://doi.org/10.4143/crt.2002.34.4.268
-
Abstract
PDF
- The retinoblastoma protein (pRb)/cyclin D1/ p16 pathway plays a critical role in controlling the progression from G1 to S phase of the cell cycle. Abnormal expression of the individual components of the pathway has been reported in many human cancers, including the breast. Our aim was to investigate the role of this pathway in tumorigenesis and tumor progression, and to evaluate the value of these oncoproteins as potential prognostic factors in breast cancer.
MATERIALS AND METHODS
We examined the significance of the p16, pRb, and cyclin D1 expression in 128 cases of invasive breast carcinomas using immunohistochemistry on formalin fixed, paraffin sections. The results correlated with the survival rate and clinicopathologic variables, including age, histologic grade, lymph node status, tumor size, estrogen receptor (ER) and progesterone receptor (PR) content. The negative finding for nuclear staining for pRb and p16 were defined as abnormal.
RESULTS
Abnormal expression of the p16 and pRb were seen in 21% and 43% of tumors, respectively. There was a significant inverse relationship between the p16 and pRb expressions. There was no association between the p16 staining and any other parameters, including survival rate, cyclin D1, or clinicopathologic variables. Surprisingly, there was a trend for pRb positive tumors to be grade III ductal carcinomas. Cyclin D1 positivity was noted in 46% of cases. The expression of cyclin D1 protein was significantly higher in lower histologic grades, and with higher ER and PR expressions.
CONCLUSION
These findings suggest the p16 may be negatively regulated by the pRb, and that cyclin D1 is involved in the tumor progression in well-differentiated tumors and could be an ER and PR related protein. In a Cox multivariate analysis, the p16, pRb, and cyclin D1 were not independent predictors of patient outcome.
- 4,012 View
- 15 Download
- A Study of the Survival Rate of Childhood Cancer in Korea
- Mi Hwa Yang, Song Hyeun Eun, Chan Sook Park, Jin A Son, Jae Yun Kim, Jae Wook Ko, Don Hee Ahn
- Cancer Res Treat. 2001;33(3):191-198. Published online June 30, 2001
- DOI: https://doi.org/10.4143/crt.2001.33.3.191
-
Abstract
PDF
- PURPOSE
It is known that the prognosis of childhood cancer is relatively good, however actual representative nationwide data on childhood cancer, particularly of survival rate, are rare. In this study we attempted to establish the overall survival rate of major childhood cancer.
MATERIALS AND METHODS
The primary source of data of childhood cancer under 15 years of age were the registry files of the Central Cancer Registry Report (Ministry of Health & Welfare) from 1993 to 1997. The above data was compared to death case data files of the same period obtained from the Korea National Statistical Office using the personal identification code. We calculated the 1, 3, and 5 year survival rates using the life table of SPSS and Kaplan-Meier method and compared the survival rate of disease according to prognostic factors.
RESULTS
A total of 6,720 cases of pediatric cancer from the Central Cancer Registry files were computerized and sorted by personal identification (ID) code to extract duplicated cases as well as cases with incomplete data. The final number of cases entered in this study was 4,983. 1) The number of confirmed death cases was 1,448 (29.1%). 2) The disease distribution showed that the most common pediatric cancer was leukemia (1,468/4,983, 29%), followed by brain tumors (503/4,983, 10%), lymphoma (315/4,983, 6%), Wilms tumor (165/4,983, 3%), etc. in order by number of patients. 3) The 5 year survival rate of disease was as follows: overall 62%, acute lymphocytic leukemia 61%, acute non-lymphocytic leukemia 32%, malignant lymphoma 72%, neuroblastoma 47%, medulloblastoma 51%, Astrocytoma 66%, Wilms tumor 83%, etc.
CONCLUSION
We analyzed and report the 5 year survival rate of overall childhood cancer and of each of the twelve major childhood cancers from in Korea 1993 to 1997 to provide basic data on childhood cancer statistics. -
Citations
Citations to this article as recorded by- Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study
Kyung-Nam Koh, Ho Joon Im, Hyery Kim, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Hyo Seop Ahn, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Young Tak Lim, Jun Eun Park, Byung-Kiu Park, Hyeon Jin Park, Jong Jin Seo
Journal of Korean Medical Science.2017; 32(4): 642. CrossRef - Inequalities in childhood cancer mortality according to parental socioeconomic position: A birth cohort study in South Korea
Mia Son, Jongoh Kim, Juhwan Oh, Ichiro Kawachi
Social Science & Medicine.2011; 72(1): 108. CrossRef - Korean Pediatric/Adolescent Lymphoma - Incidence and Pathologic Characteristics -
Seung-Sook Lee, Jin-Man Kim, Young-Hyeh Ko, Jooryung Huh, Chang Suk Kang, Chul Woo Kim, Yun Kyung Kang, Jai Hyang Go, Min Kyung Kim, Wan-Seop Kim, Yoon Jung Kim, Hyun-Jung Kim, Hee Kyung Kim, Jong Hee Nam, Hyung Bae Moon, Chan-Kum Park, Tae In Park, Young
The Korean Journal of Pathology.2010; 44(2): 117. CrossRef - Clinical Results of Chemotherapy based Treatment in Retinoblastoma Patients: A Single Center Experience
Hyery Kim, Ji Won Lee, Hyoung Jin Kang, Hyeon Jin Park, Yoon Yi Kim, Hee Young Shin, Young Suk Yu, Il Han Kim, Hyo Seop Ahn
Cancer Research and Treatment.2008; 40(4): 164. CrossRef - Clinicopathologic Features and Treatment Outcomes in Malignant Lymphoma of Pediatric and Young Adult Patients in Korea: Comparison of Korean All-Ages Group and Western Younger Age Group
In Gyu Hwang, Keon Hee Yoo, Soo Hyun Lee, Yeon Hee Park, Tae Kyu Lim, Sang Cheol Lee, Sara Park, Byeong-Bae Park, Young Hyeh Ko, Kihyun Kim, Hong Hoe Koo, Won Seog Kim
Clinical Lymphoma and Myeloma.2007; 7(9): 580. CrossRef
- Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study
- 5,686 View
- 45 Download
- 5 Crossref
- The Survival Rate of Stage IIB Ostosarcoma after Neoadjuvant Chemotherapy ( Modified T10 Protocol )
- Jae Do Kim, Jeong Soo Bae, Myung Rae Cho
- J Korean Cancer Assoc. 1998;30(3):591-598.
-
Abstract
PDF
- PURPOSE
The survival rate according to the methods of treatment was significantly higher in the osteosarcoma patients in which limb salvage operation with neoadjuvant chemotheraphy. The purpose of this study is to analyze the results of treatment in the Stage IIB osteosarcoma patients who treated with modified T10 protocol.
MATERIALS AND METHODS
From Jun. 1990 to Oct. 1997, thirty eight cases of Enneking's stage IIB osteosarcoma in extremities, were treated with neoadjuvant chemotherapy by modified T10 protocol of Rosen. Their mean age was 22 years old (8 months to 55 years). And average duration of follow up is 29 months(10 manths to 88 months). The preoperative chemotherapy consisted of high dose methotrexate(HDMTX)(above 12 years old: 8 g/m2, below 12 years old: 12 g/m2), adriamycin(ADR)(30 mg/m2/day x 2), intraarterial cisplatin(CDDP)(100 mg/m2) or ifosfamide (IFO)(1.8 g/m2/day x5). The preoperative tailoring was performed according to the radiologic response after chemotherapy. If the patient revealed good response, we continued the chemotherapy next one more cycle and if not, stoped the chemotherapy or changed the cisplatin to ifosfamide. The postoperative chemotherapy consisted of HDMTX, adriamycin, ifosfamide or cisplatin with 4 cycles. According to the pathologic response to the pre-operative chemotherapy, we use HDMTX, ADR, CDDP in good response group and HDMTX, ADR, IFO in poor response group respectively.
RESULTS
On the latest follow up, 27 patients were continuous disease free(CDF 27/38), 4 patients were alive with disease(AWD) and 6 patients were died of disease(DOD) and I case was died of bone marrow and hepatic failure due to complication of chemotherapy. According to Kaplan-Meier's plot, the overall 5 years survival rate was 73.6%, and continuous disease free 5 years survival rate being 64%. The comparison of continuous disease free survival rates between good radiologic response group and poor response group showed 73% and 55%. The continuous disease free survival rates according to the pathologic response in good response group and poor were 90 % and 55%. During the chemotherapy, the most serious complications were leukocytopenia and bone marrow failure. These were controled by granulocyte colony stimulating factor(G-CSF) and leukotrophic agent. Other minor complications were nausea, vomiting, headache and extrapyramidal symptom, which were easily managed by simple conservative measure.
CONCLUSION
It was obtained that the overall 5 years survival rate was 73.6%, and continuous disease free 5years survival rate being 64% with modified T10 protocol.
- 4,349 View
- 26 Download
- Treatment Result of Pediatric Osteosarcoma with Intraarterial Cisplatin
- Hyoung Soo Choi, Hyoung Jin Kang, Jun Ah Lee, Hyo Heong Han, Hyeon Jin Park, Eun Sun Yoo, Woo Sun Kim, Hee Young Shin, In One Kim, Sang Hoon Lee, Hyo Seop Ahn, Han Koo Lee
- J Korean Cancer Assoc. 1998;30(1):169-177.
-
Abstract
PDF
- PURPOSE
This study was performed to determine the outcome after treatment of osteosarcoma with intraarterial cisplatin as a preoperative chematherapy regimen.
MATERIALS AND METHODS
Twenty five patients with extremity osteosarcoma were treated with intraarterial cisplatin at Seoul National University Children's Hospital from January 1987 to April 1996. The dose of cisplatin was 130 mg/m2 and three to six courses were repeated two- to three-week intervals, Systemic doxorubicin was added to six of these patients. This was followed by surgical resection(limb salvage or amputation) and postoperative adjuvant chemotherapy.
RESULTS
Limb-salvage was possible in twenty of these twenty five patients. Pulmonary metastasis was present in five patients at diagnosis and developed later in three patients. In six patients treated with systemic doxorubicin, pulmonary metastasis was absent at diagnosis and during follow-up period. Local recurrence after limb salvage was occurred in one patient and treated with amputation and systemic chemotherapy. Seven patients died from pulmonary metastssis and one from unknown cause. The follow-up duration of these patients was three to eighty eight months(median twenty two months) and the overall five-year survival and event free survival rate were 62.1% and 57.5%, respectively.
CONCLUSION
These data demonstrate that intraarterial cisplatin can be used as an effective regimen preoperatively for pediatric patients with extremity osteosarcoma. The combined use of systemic doxorubicin is expected to improve survival in patients with pulmonary metastasis.
- 3,730 View
- 18 Download
- Primary Intestinal Lymphoma Treatment Results and prognostic Factors in 52 Cases
- In Chul Hong, Chang Hak Yoo, Sung Hoon Noh, Chang Hwan Cho, Kyung Shik Lee
- J Korean Cancer Assoc. 1998;30(1):158-168.
-
Abstract
PDF
- PURPOSE
In spite of many published reports about the primary gastrointcstinal lymphoma in Korea, the majority of them unfortunately involved a small number of patients with diverse results conceming treatment, patient survival, and prognostic factors. There also were few reports mainly focusing on primary intestinal lymphoma alone. Therefore we studied the patient-survival and prognostic factors in 52 cases of intestinal lymphomas.
MATERIALS AND METHODS
We reviewed fifty two patients who received treatment due to primary intestinal lymphoma at Severance hospital, from January 1980 to June 1995.
RESULTS
The intestinal lymphomas were located in descending order of frequency at the terminal ileum, i1eocecal region, right colon, and the jejunum. The most common histologic type was diffuse large cell type and the majority showed an intermediate grade of differentiation. The average survival time was 40.7 months with a 5 year survival rate of 41.4%. The overall and complete remission rate of the intestinal lymphoma were 76.2%, 64.3%, respectively. Additional chemotherapy or radiotherapy to surgery improved remission rate. The overall 5 year survival rates were 50.4%, 47.3%, 33.3%, and 25.0% in stage I, II1, II2 and III~IV, respectively. The 5 year survival rate after curative resection was 57.0% and 16.6% after incomplete resection. The significant prognostic factors were residual tumor, site of the lesion, multiplicity, and adjacent organ invasion. However, the site of the lesion alone (worst in the jejunum) was the sole independent variable on multivariate analysis.
CONCLUSION
We concluded that early diagnosis and curative resection were important to improve survival rates in the primary intestinal lymphoma. More number of such cases are needed for further comparison of various treatment methods and results.
- 3,558 View
- 15 Download
- Treatment of Childhood Acute Lymphoblastic Leukemia Diagnosed Jan . , 1978 Through Dec . , 1987 : Comparison between Standard - Risk and High - Risk Groups
- Soon Ki Kim, Hee Young Shin, Hyo Seop Ahn
- J Korean Cancer Assoc. 1990;22(3):539-549.
-
Abstract
PDF
- Of 328 children who were diagnosed as acute lymphoblastic leukemia at the Department of Pediatrics. Seoul National University Hospital from Jan., 1978 through Dec., 1987, 211 patients above one year af age were evaluable for induction chemotherapy. The leukemias were classified as standard risk (SR), comparison group (who had high-risk prognostic factors, but had been treated with standard regimen), or high- risk (HR) leukemia according to the prognostic criteria at diagnosis. Three regimens were compared and the results were as follows. 1) The complete remission (CR) rate was 97.1%(133/137), 81.0%(34/42) and 90.6%(29/32) in SR, comparison group. and HR group, respectively. And significant difference in the CR rate was seen between SR group and comparison group (p= 0.0001). 2) Of the patients remained in remission follow-up of each group showed 56.8% 5-yr disease-free survival (DFS)(+-5.9%, median follow-up 30 mo) in SR, 35.5% (+-9.1%, median 24 mo) in comparison group, and 76.0%(+- 8.5%, median 24 mo) in HR group. And significant difference in the 5yr-DFS rate were observed be(ween SR and comparison group (P = 0.007), between HR and comparison group (p = 0.002), respectively. 3) Induction failure was due to infection (n=2) bleeding (n=1) or uric acid nephropathy (n= 1) in SR drug resistance (n=3), infection (n=2), bleeding (n=2), or combind infection and bleeding (n=1) in comparison group, and bleeding (n=2) or infection (n= 1) in HR. Of the patients who were on maintenance chemotherapy in complete remission, 11 died due to infection: menigitis or meningoencephalitis (n=4), disseminated varicella (n=3), Pneumocystis carinii pneumonia (n=2), and sepsis (n=2). 4) In SR group, 29 patients experienced relapse: BM(n=18), CNS(n=3), BM and CNS(n=4), and testes (n=4). Two- third (n = 19) of them relapsed between 6mo to 2yr after initial remission. In comparison graup, 20 relapsed: BM (n= 10), CNS(n=2), BM and CNS (n=3), testes (n=4), and testes and CNS(n =1), Mostly they relapsed within the first 2 years after remission. In HR group, all patients (BM 3 and CNS 1) experienced relapse from 1 yr to 1 1/2 yr after initial remission.
- 2,677 View
- 15 Download
- A Clinical Study of 500 Cases of Breast Cancer
- In Sik Park, Ja Yun Koo, Hy De Lee, Woo Hee Jung
- J Korean Cancer Assoc. 1997;29(6):1061-1068.
-
Abstract
PDF
- PURPOSE
We investigated the clinical characteristics of breast cancers and its significance. MATERIAL AND METHOD: We evaluated the clinical characteristics of 500 women with breast cancer who were diagnosed and treated by one surgeon between March 1991 and August 1996.
RESULTS
The median age was 46.7 years and the most common age group was 40's. The presenting symptoms for most patients were palpable mass (75.2%) followed by abnormal mammographic findings (8.4%), pain (6.3%) and nipple discharges (4.7%), and the duration of symptoms was less than 1 month in 41.4%. Fifty three percent of the 500 cases had T2 lesion (size; 2 to 5 cm). With the increase of tumor size, overall and disease free survival rates (OS, DFS) were decreased. Surgical treatment consisted of modified radical mastectomy (52.8%) and partial mastectomy (33.6%) The most common stage was II (42.3%) and the early breast cancer (stage 0, I, II) was 388cases (78.1%) and the stage were inversely correlated with DFS and OS. The positivity of axillary lymph node was 39.3% and the number of the metastatic lymph nodes was inversely correlated with DFS and OS. The pathologic types were infiltrating ductal carcinoma (83.0%), ductal carcinoma in situ (12.8%), infiltrating lobular carcinoma (1.2%), lobular carcinoma in situ (0.4%) and Paget's disease (2.0%). ER positivity was 48.9% and PR 46.9%. ER positive patients showed survival benefit compared to ER negative patients. The common sites of distant metastases were lung, bone and liver.
CONCLUSIONS
Our patients with breast cancer were younger than those of western and showed the impacts on survival according to the lymph node status,tumor size.
- 2,885 View
- 13 Download
- A Multivariate Analysis of Prognostic Factors of 3176 Gastric Cancers
- Uck Sang Zung, Chung Han Lee, Sung Uhn Baek, Kyung Hyun Choi, Seung Do Lee
- J Korean Cancer Assoc. 1994;26(2):179-188.
-
Abstract
PDF
- Between l980 and 1992, 3176 consecutive patients with adenocarcinoma of stomach under-went surgical treatment at Department of Surgery, Kosin Medical College. Follow up rate was 96.5%. The overall operative mortality rate was 1.26%. The overall cumulative survival rate was 74.5% at 1 year, 62.1/ at 2 years, 56.0% at 3 years, 52.0% at 4 years, 48.8% at 5 years, and median survival time was 53 months. The cumulative survival rate of radical resection group was 90.2% at 1 year, 78.2% at 2 years, 72.8% at 3 years, 68.3% at 4 years, 63.9% at 5 years, and median survival time was 141 months. To determine the progrostic factors, 9 variables were chosen; age, sex, location of tumor, size of tumor, Borrmann type, tumor invasion, lymph node metastasis, distant metastasis end stage. Survival rate was examined using Kaplan-Meier method. The prognostic factors were examined for their relationship to survival rate using Cox's Proportional Hazard Model The most important prognostic factor is distant metastasis(2.88 of hazard ratio). Other factors such as lymph node metastasis, tumor invasion, size of tumor were also important factors in gastric cancer patients. Improvement of the prognosis of stomach cancer will require early detection of gastric cancer, and more curative resection.
- 3,151 View
- 15 Download
- The Prognostic Effects of Spleen Preservation in The Radical Total Gastrcomy
- Hee Duck Kim, Chung Han Lee, Kyung Hyun Choi, Seung Do Lee, Jae Kwan Suh
- J Korean Cancer Assoc. 1994;26(2):198-208.
-
Abstract
PDF
- In Gastric Cancer Surgery, an extended radical operation is common procedure, and in cases of total gastrectomy, there is a tendency to perform splenectomy at the same time. However, regarding to the prophylactic splenectamy for clearing of spleen hilar nodes the prognostic ef- fectivity is controversiaL We studied the value of spleen preservation in total gastrectomy for gastric cancer by survival rate, according to tumor stage and tumor location and by inflammatory complications. And another study was done on cellular immunity of total gastrectomy patients by T-cell subset(T3T4T5 & T4T8 Ratio) and Natural Killer cell activity changes(preoperative day and postoperative 2 months) with or without combined splenectomy. In five year survival rate of stage I and II groups, spleen preserving group(78.7%) has better prognosis than splenectomized group(70.4%) and in stage III and IV groups, 5 year survival rate of nonsplenectomized cases(30%) showed higher than that of splenectomized cases(17%). Five year survival rate of nonsplenectomized, proximal gastric cancer group(57.5%) showed significantly better than that of splenectomized group(30%). Postoperative T4/T8, ratio and NK cell activity were markedly decreased compared to preoperative ratio in the splenectomized group than the non-splenectomized and control groups. Consequently spleen preserving group group had better prognosis than splenectomized group in total gastrectomy, which may be attributable in part to reduction of cellular immunity caused by splenectomy. It seems to be desirable that accordingly prophylactic splenectomy in gastric cancer surgery should be reconsidered.
- 2,649 View
- 12 Download
- Breast Cancer Detected by Screening Mammography
- Byung Ho Son, Jung Mi Park, Gyeong Yeop Gong, Se Hyun Ahn
- J Korean Cancer Assoc. 1999;31(3):499-508.
-
Abstract
PDF
- PURPOSE
The early detection of breast cancer by screening mammography is important to reduce breast cancer mortality rate. The purpose of this study was to investigate the characteristics of breast cancer patients detected by screening mammography.
MATERIALS AND METHODS
Surgically treated 1,265 patients at Asan Medical Center from Jul. 1989 to Dec. 1997 were evaluated. Among them, 119 patients (9.4%) were detected by screening mammography. These patients were compared with clinically detected symptomatic breast cancer group.
RESULTS
The characteristics of breast cancer patients detected by screening mammography were as follows: The most common finding of mammography was microcalcifications (62.2%); The less invasive or more conservative minimal and non-destructive surgical treatments such as breast conserving surgery (21.0%), simple mastectomy (8.4%), breast reconstruction (8.4%) were performed more frequently; The median tumor size of invasive cancers was 16 mm; Node-negative cancers (83.2%) were more frequent; The early breast cancer of stage 0 and I was 70.6%; DCIS (29.4%) was highly proportionated; and The 5-year overall (95.8%) and 5-year disease-free survival rate (92.0%) were significantly higher than in clinically detected symptomatic breast cancer patients.
CONCLUSION
The screening mammography was significant for detecting non-palpable, early stage breast cancer. Ultrasonography was needed as an adjunct for the accurate detection in dense breast or young women. According to early detection, the 5-year survival rate was high.
- 3,196 View
- 19 Download
- Results of Surgical Treatment and Analysis of Prognostic Factors in Primary Gastric Adenocarcinoma
- Cheol Hun Chung, Young Jae Mok, Gil Soo Son, Seung Joo Kim, Sae Min Kim
- J Korean Cancer Assoc. 1999;31(3):458-465.
-
Abstract
PDF
- PURPOSE
Despite gsstric cancer is one of the most common ma1ignancies, its prognosis has not been improved significantly. Therefore, it is important to know what clinical and pathological factors relate to survival in gastric carcinoma in order to improve survival rate. The aim of this retrospective study was to evaluate treatment results and to analyze the factors that affect the survival of patients with gastric carcinoma.
MATERIALS AND METHODS
A total of 1,580 patients with primary gastric adenocarcinoma who had been treated surgically during the period 1983-1996 at the Department of Surgery, Korea University College of Medicine was studied to evaluate the treatment outcome. Prognostic factors were investigated by univariate and multivariate analyses in 1,407 resected patients.
RESULTS
The 5-year survival rate was 57.1% in all case, 62.4% in resected cases, and there was no survivor at 2.5 year in unresectable cases. In univariate analysis, gross type, maximum tumor diameter, depth of invasion, lymph node involvement, distant metastasis, histologic type and type of operation were found to correlate significantly with survival. Multivariate analysis indicated that lymph node involvement, depth of invasion and type of cancer were independently conelated with survival. The stage-related survival rates (UICC, 1987) were 95.8% (stage Ia), 87.6% (stage Ib), 76.7% (stage II), 51.3% (stage 1IIa), 25.5% (stage IIlb), 9.4% (stage IV) and the stage-related survival rates (UICC, 1997) 95.8% (stage Ia), 87.6% (stage Ib), 76.4% (stage II), 55.2% (stage IIla), 24.0% (stage IIIb), 13.4% (stage IV). There was no difference between two staging systems.
CONCLUSIONS
These results suggest that lymph node involvement, depth of invasion, and gross type were the most important prognostic factors, indicating that they may be helpful as predictors of long-term survival and in planning the treatment.
- 2,942 View
- 13 Download
- Analysis of 103 Patients with Unknown Primary Carcinoma: Retrospective Study
- Jae Jin Lee, Si Young Kim, Kyung Sam Cho, Juhie Lee, Hwi Joong Yoon
- J Korean Cancer Assoc. 2001;33(1):1-8.
-
Abstract
PDF
- PURPOSE
Unknown primary carcinoma takes up approximately 0.5-10% of the oncology patients evaluated, and the patients have poor survival of between 3 to 11 months. Despite the short survival, certain clinically defined subsets of patients were reported to have a better prognosis. Thus, the objective of this study was to identify prognostic factors.
MATERIALS AND METHODS
The present study was con ducted with 103 patients who were referred from January 1988 to July 1999. The primary end point was survival. The survival curves were estimated using the Kaplan-Meier method and compared using the Log-rank test and Cox's proportional hazards regression analysis.
RESULTS
Most patients had histologic evidence of ade nocarcinoma or squamous cell carcinoma. Univariate and multivariate analyses identified good prognostic factors including performance status (grade 0-2), female and adenocarcinoma with more than moderate level of differentiation. The responders of chemotherapy in squamous cell carcinoma and lung, breast, ovary -estimated- cancer showed good survival rates.
CONCLUSION
Unknown primary carcinoma tended to show a poor prognosis. However, when treatment modality of unknown primary carcinoma is to be determined through the prognostic factors, the patients quality of life can be improved through reducing the treatment side effects and economic burden on the patients.
- 3,540 View
- 34 Download
- Evaluation of the New UICC Staging System for Gastric Carcinoma
- Hyeong Myeong Back, Sung Joon Kwon, Oh Jung Kwon, Pah Jong Jung, Kwang Su Lee, Jin Young Kwak, Kyu Young Jun, Chi Kyu Won
- J Korean Cancer Assoc. 1999;31(1):54-61.
-
Abstract
PDF
- PURPOSE
There are several kinds of classificatian dealing with the staging of the gastric adenocarcinoma. However, such different staging systems pose difficulty in the inter- institutional or intemational comparison of the disease status and the treatment results. The purpose of this study is to evaluate each staging system and to assess the usefulness of the new UICC-TNM staging system (1997) for gastric adenocarcinoma. MATERIAL AND METHODS: We retrospectively analysed 473 cases of gastric adenocarcinoma who were operated at the Department of General Surgery, Hanyang University Hospital during the period from 1992 to 1996. Using these cases, we analyzed their cumulative 5-year survival rate according to three kinds of staging systems; old UICC-TNM staging system (1987), new UICC-TNM staging system (1997), and the Japanese staging system for gastric carcinoma (1993).
RESULTS
The follow up rate was 94.3% and the median follow up period was 30.3 months. All of these three systems showed a statistically significant survival difference according to their different classifications. When the distribution of stage between old and new UICC-TNM staging system was compared, 95 cases (20.1%) were subjected to stage shifting, which involves 12.1% of up-staging and 8.4% of down-staging. Stage shifting was most prominent in stage IIIb (68.8%). The cumulative 5-year survival rate according to the new UICC-TNM staging system was 99.1% in stage Ia, 81.4% in stage Ib, 75.2% in stage II, 45.9% in stage IIIa, 21.0% in stage IIIb, and 19.4% in stage IV.
CONCLUSION
We conclude that the new UICC-TNM staging system is simple, practically convenient, and highly reproducible, and it showed a statistically significant survival difference according to their staging classification.
- 3,416 View
- 12 Download
- Treatment Results of Radiation Therapy in Laryngeal Cancer
- Hong Seok Jang, Sei Chul Yoon, Sei Chul Yoon, Ki Mun Kang, Chul Seung Kay, Min Sik Kim, Byung Do Suh, Hoon Kyo Kim, Kyung Shik Lee, Kyung Sub Shinn
- J Korean Cancer Assoc. 1994;26(6):950-959.
- 3,372 View
- 14 Download
- Anti-tumor Effects of extracts of Pulsatilla koreana ( SB-31 ) in vitro
- Sam Yong Kim, Song Bae Kim
- J Korean Cancer Assoc. 1994;26(6):959-964.
-
Abstract
PDF
- Extracts of P. koreana(SB-3l) has been tried as an antitumor agent by traditional medicine practitioner in Korea for the past 30 years. It is a specially prepared extract af P. koreana whose fractions lose efficacy compared to the original mixture. Lee" observed substantial antitumor effects and minimal toxicity of SB-31 in sarcoma 180 animal tumor model(unpublished data). For the past 5 ears, there has been dramatic though anecdotal therapeutic outcomes with SB-3l in some advanced stage cancer patients. We evaluated the in vitro antitumor effects of SB-31 against 3 kinds of gastric cancer cells, A549, HeLa and Caski, MCF7, HepG2 and Hep3B and normal mononuclear cells. Cytotoxicity ws evaluated with the Tetrazolium-based colori- metric assay(MTT) after incubation of cancer cells with SB-31. Results; in 3 gastric cancer cells, ID of SB-31 were 0.16, 0.34 and 0.53 mg/mL Most effective tumor cell kill was achieved after 96 hrs of incubation with SB-31. The ID values of SB-31 on various cancer cell lines ranged from 0.14 mg/ml to 0.27 mg/mL Keeping SB-31 ampul in room temperature up to 4 days did not affect the efficacy but the activity decreased after more than 4 days in the ambient temperature. It is concluded that SB-31 is an active antitumor agent without significanct toxicity. The mechanism of action of SB-31 and its toxicity and efficacy should be further evaluated.
- 3,038 View
- 34 Download
- Analysis of Recurrence and Survival Rate in Early Gastric Castric Cancer Patients
- Seong Kwang Chang, Nam Sun Paik, Nan Mo Moon, Ho Yoon Bang, Jong Inn Lee, Dong Wook Choi
- J Korean Cancer Assoc. 1996;28(6):1021-1032.
-
Abstract
PDF
- The prognosis of surgically treated early gastric cancer(EGC) is usually excellent and the recurrence rate is quite low. From January l985 to December l993, 708 cases of EGC among 4408 cases of gastric cancer underwent gastrectomy in Korea Cancer Center Hospital. Among them 619 cases could be followed-up, and disclosed 24 cases(3.9%) of recurred EGC. 5 and 10 year survival rate in EGC exclusive of other cause of death were 95.8% and 95.4%. Mean interval between surgery and recurrence was 31.7 month and mean survival time was 40.3 month. Retrospective analysis was performed to evaluate the clinicopathological factors which relate to recurrence and survival rate. In univariated and multivariated analysis of factors, statistically significant prognostic factors are regional lymph node metastasis and macroscopically elevated type(p<0.05). Mode of recurrence in EGC was commonly hematogenous metastasis(69.7%), and frequent metastatic sites were liver, bone and lung
- 3,741 View
- 25 Download
- Histocompatibility Antigens in Primary Gastric Carcinoma in Young Korean Adults
- Tai Ho Chung, Jung Chul Kim, Da Mi Lee, Suk Joo Lee, Soo Il Chang, Wan Sik Yu, In Sun Lee
- J Korean Cancer Assoc. 1996;28(6):1032-1040.
- 2,756 View
- 15 Download
- End Results of Surgical Treatment of 354 Patients with Gastric Adenocarcinoma
- Kyung Suk Chung, Sung Ha Moon, Hyun Wook Shin, Young Cheol Lee, Joo Seop Kim, Bong Wha Chung, Jae Jung Lee, Chul Jae Park, Young Cheol Jeon, Myung Seok Lee, Woo Joong Kim
- J Korean Cancer Assoc. 1995;27(1):28-35.
-
Abstract
PDF
- The surgical results of 354 patients with gastric adenocarcinoma treated at the Department of Surgery, Kangnam Sarced Heart Hospital, Hallym University from l984 to 1993 were report- ed. The survival rate of the 354 patients was compared with reference to categories of prognostic factors(univariate analysis) and significant factors affecting survival were identified by multivariate analysis using the Cox's proportional hazard model. The resection rate was 93.5% and the operative mortality within 1 month was 2.5%. The 5- year survival rates were 49.2% for the entire group of patients, 52.0% for patients who under-went resection, 72.3% for patients who underwent curative resection, and 18.4% for patients who underwent palliative resection. The 5-year survival rates according to the TNM stage were 85.4% for stage I, 56.0% for stage II, 38.2% for stage III, and 10.3% for stage IV. Univariate analyses showed a significant difference in survival in relation to age, primary tumor factor(T), reaional lymph node factor(N), distant metastasis factor(M), macroscopic type, size of tumor, type of operation, TNM stage and curability of surgery. Multivariate analysis using the Coxs proportional hazard model in a stepwise fashion identified a final set of three significant variab1es: curability of surgery(P=0.0002), TNM stage(P=0.0007), and macroscopic type(P=0.0008). These results suggest that continuing efforts to increase rate of less advanced cancers and curative resection with systematic lymph node dissection in advanced cancers are necessary for an improvement of the end results of surgical treatment.
- 3,550 View
- 12 Download
First
Prev
